Henk-Jan Guchelaar
Professor of Clinical pharmacy
- Name
- Prof.dr. H.J. Guchelaar
- Telephone
- +31 71 526 2790
- h.j.guchelaar@lumc.nl
- ORCID iD
- 0000-0002-7085-1383
Henk-Jan Guchelaar is professor Clinical Pharmacy at both the Leiden University Medical Center (LUMC) and the faculty of Math & Natural Sciences of the University of Leiden (LACDR). He is head of the department of Clinical Pharmacy & Toxicology of the LUMC and program leader of the research program ‘Personalised Therapeutics’. He is also director of the Leiden University research profile ‘Translational Drug Discovery and Development’ and founder of the Master Pharmacy. In addition, he coordinates a European Horizon 2020 project about implementation of pharmacogenetics in routine health care. Guchelaar is board member of division 4 of the LUMC. He is also clinical trainer Clinical Pharmacology and deputy clinical trainer Hospital Pharmacy.
Henk-Jan Guchelaar is professor Clinical Pharmacy at both the Leiden University Medical Center (LUMC) and the faculty of Math & Natural Sciences of the University of Leiden (LACDR). He is head of the department of Clinical Pharmacy & Toxicology of the LUMC and program leader of the research program ‘Personalised Therapeutics’. He is also director of the Leiden University research profile ‘Translational Drug Discovery and Development’ and founder of the Master Pharmacy. In addition, he coordinates a European Horizon 2020 project about implementation of pharmacogenetics in routine health care. Guchelaar is board member of division 4 of the LUMC. He is also clinical trainer Clinical Pharmacology and deputy clinical trainer Hospital Pharmacy.
Clinical Pharmacy
Clinical Pharmacy entails providing and guaranteeing effective, save and efficient pharmacotherapy for patients being treated both within the LUMC and, in case of LUMC-guided and/or –initiated treatment, outside the LUMC. In particular, providing specialised pharmaceutical patient care in the context of pharmacotherapy and clinical toxicology is important. In education, clinical pharmacy includes coordinating and providing training and education in (hospital)pharmacy, medicines, clinical pharmacology, pharmacotherapy and pharmacotoxicology. Clinical Pharmacy is oriented towards the patient as well as the pharmaceutical product, the latter by manufacturing and analysing medicines.
The research of Henk-Jan Guchelaar focuses entirely on ‘personalised therapeutics’. The discovery of pharmacogenetic biomarkers in cancer, the implementation of these biomarkers in clinical practice and the development of personalised therapies are the central themes within his field of research. This topic is considered very important in Europe and fits perfectly within the National Science Agenda route ‘personalised medicine’. In 2016, Guchelaar started a European collaboration project (Horizon 2020) which measures the effects of adapting drug prescriptions based on pharmacogenetic biomarkers using pharmacogenetic guidelines on treatment outcome and health care costs. In 2017 he has, in collaboration with several departments of the LUMC, the Leiden Academic Center for Drug Research (LACDR) and a number of companies at the BioScience Park in Leiden, initiated the ‘Leiden Network for Personalised Therapeutics’ (LNPT). Within this network fundamental and clinical researchers closely collaborate in the field of individualised therapy development.
Academic career
Henk-Jan Guchelaar has completed his education Pharmacy (cum laude) and doctoral research at Groningen University, the Netherlands. The title of his doctoral thesis (1993) is ‘Modulation of cisplatin activity and toxicity; changing the drug or changing the target’. Guchelaar performed a clinical orientation at the New England Medical Centre Hospital in Boston, USA. After his graduation, Guchelaar further specialised in hospital pharmacy and clinical pharmacology at the University Medical Centre Groningen. In 2003, he was appointed professor Clinical Pharmacy at the LUMC, and in 2008 of the LACDR, University of Leiden. The title of his inaugural lecture was ‘(Bij)werking begrepen’.
Over 20 years, Henk-Jan Guchelaar performs research in the field of ‘Personalised Therapeutics’ with a strong focus on pharmacogenetics and oncology. He published over 300 scientific publications and at least 30 graduate students graduated under his supervision. Prof. Guchelaar has held a number of national and international offices at scientific organisations. Currently he is vice-chair of the Dutch Society of Clinical Pharmacology & Bio-Pharmacy; chair of the Concilium Hospital Pharmacy; member of the CCMV; college member of the College for Evaluation of Medicines; member of the scientific program committee of the American Society of Clinical Pharmacology & Therapeutics; member of the Scientific Advisory Board of KiKa; vice-chair of the committee Pharmaceutical Help (Zorg Instituut Nederland); member of the Council for Medical Sciences (KNAW); member of the Royal Dutch Society of Sciences.
Professor of Clinical pharmacy
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
Professor Clinical Pharmacy
- Faculteit Geneeskunde
- Divisie 4
- Klinische Farmacie en Toxicologie
- Marok, F.Z.; Wojtyniak, J.G.; Selzer, D.; Dallmann, R.; Swen, J.J.; Guchelaar, H.J.; Schwab, M. & Lehr, T. (2024), Personalized chronomodulated 5-Fluorouracil treatment, Clinical Pharmacology & Therapeutics.
- Klomp, S.D.; Veringa, A.; Alffenaar, J.W.C.; Boer, M.G.J. de; Span, L.F.R.; Guchelaar, H.J. & Swen, J.J. (2024), Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole, Clinical and Translational Science 17(7).
- Knikman, J.E.; Zhai, Q.L.; Lunenburg, C.A.T.C.; Henricks, L.M.; Boehringer, S.; Lee, M. van der; Man, F.M. de; Offer, S.M.; Shrestha, S.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Schaik, R.H.N. van; Gelderblom, H.; Mathijssen, R.H.J.; Schellens, J.H.M.; Cats, A.; Guchelaar, H.J. & Swen, J.J. (2024), Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD , Genome Medicine 16.
- Samarasinghe, S.R.; Hoy, W.; Jadhao, S.; McMorran, B.J.; Guchelaar, H.J. & Nagaraj, S.H. (2023), The pharmacogenomic landscape of an Indigenous Australian population, Frontiers in Pharmacology 14.
- Guchelaar, H.J. & Swen, J. (2023), Reply to: Temporary Like Achilles: Pre-emptive germline pharmacogenetic testing, Basic and Clinical Pharmacology and Toxicology 133(4): 400-401.
- Peruzzi, E.; Roncato, R.; Mattia, E. de; Bignucolo, A.; Swen, J.J.; Guchelaar, H.J.; Toffoli, G. & Cecchin, E. (2023), Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice, British Journal of Clinical Pharmacology.
- Peeters, S.L.; Deenen, M.J.; Thijs, A.M.; Hulshof, E.C.; Mathijssen, R.H.; Gelderblom, H.; Guchelaar, H.J. & Swen, J.J. (2023), UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety, Pharmacogenomics 24(9): 435-439.
- Knikman, J.E.; Lopez-Yurda, M.; Meulendijks, D.; Deenen, M.J.; Schellens, J.H.M.; Beijnen, J.; Cats, A. & Guchelaar, H.J. (2023), A nomogram to predict severe toxicity in DPYD wild-type patients treated with capecitabine-based anticancer regimens, Clinical Pharmacology & Therapeutics 115(2).
- Shadid, I.L.; Brustad, N.; Lu, M.D.; Chawes, B.L.; Bisgaard, H.; Zeiger, R.S.; O'Connor, G.T.; Bacharier, L.B.; Guchelaar, H.J.; Litonjua, A.A.; Weiss, S.T. & Mirzakhani, H. (2023), The impact of baseline 25-hydroxyvitamin D level and gestational age on prenatal vitamin D supplementation to prevent offspring asthma or recurrent wheezing, The American Journal of Clinical Nutrition 117(6): 1342-1352.
- Souwer, E.T.D.; Sanchez-Spitman, A.; Moes, D.J.A.R.; Gelderblom, H.; Swen, J.J.; Portielje, J.E.A.; Guchelaar, H.J. & Gelder, T. van (2023), Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer, Breast Cancer Research and Treatment 199.
- Knikman, J.E.; Rosing, H.; Guchelaar, H.J.; Cats, A. & Beijnen, J.H. (2023), Assay performance and stability of uracil and dihydrouracil in clinical practice, Cancer Chemotherapy and Pharmacology 91(3): 257-266.
- Knikman, J.E.; Vries, N. de; Rosing, H.; Cats, A.; Guchelaar, H.J. & Beijnen, J.H. (2023), Development of a UPLC-MS/MS assay for the quantitative determination of capecitabine, 5′-deoxy-5-fluorocytidine (5′-dFCR), 5′-deoxy-5-fluorouridine (5′-dFUR), 5′-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL), PHARMAZIE 78(8): 107-112.
- Lyousoufi, M.; Lafeber, I.; Kweekel, D.; Winter, B.C.M. de; Swen, J.J.; Brun, P.P.H. le; Bijleveld-Olierook, E.C.M.; Gelder, T. van; Guchelaar, H.J.; Moes, D.J.A.R. & Schimmel, K.J.M. (2023), Development and bioequivalence of 3D-Printed medication at the point-of-care, Clinical Pharmacology & Therapeutics 113(5).
- Hurkmans, E.G.E.; Klumpers, M.J.; Dello Russo, C.; Witte, W. de; Guchelaar, H.J.; Gelderblom, H.; Cleton-Jansen, A.M.; Vermeulen, S.H.; Kaal, S.; Graaf, W.T.A. van der; Flucke, U.; Gidding, C.E.M.; Schreuder, H.W.B.; Bont, E.S.J.M. de; Caron, H.N.; Gattuso, G.; Schiavello, E.; Terenziani, M.; Massimino, M.; McCowage, G.; Nagabushan, S.; Limaye, A.; Rose, V.; Catchpoole, D.; Jorgensen, A.L.; Barton, C.; Delaney, L.; Hawcutt, D.B.; Pirmohamed, M.; Pizer, B.; Coenen, M.J.H. & Loo, D.M.W.M. te (2023), Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients , Frontiers in Pharmacology 13.
- Eektimmerman, F.; Swen, J.J.; Broeder, A.A. den; Hazes, J.M.W.; Kurreeman, F.S.; Verstappen, S.M.M.; Nair, N.; Pawlik, A.; Nurmohamed, M.T.; Dolzan, V.; Bohringer, S.; Allaart, C.F. & Guchelaar, H.J. (2023), Genome-wide association study of methotrexate-induced liver injury in rheumatoid arthritis patients, Clinical Pharmacology & Therapeutics 113(4).
- Shadid, I.L.C.; Lee-Sarwar, K.; Lu, Z.; Yadama, A.; Laranjo, N.; Carey, V.; O'Connor, G.T.; Zeiger, R.S.; Bacharier, L.; Guchelaar, H.J.; Liu, Y.Y.; Litonjua, A.A.; Weiss, S.T. & Mirzakhani, H. (2023), Early life gut microbiome in children following spontaneous preterm birth and maternal preeclampsia, iScience 26(12).
- Beunk, L.; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Guchelaar, H.J.; Houwink, E.J.F.; Risselada, A.; Rongen, G.A.P.J.M.; Schaik, R.H.N. van; Swen, J.J.; Touw, D.; Westrhenen, R. van; Deneer, V.H.M. & Weide, J. van der (2023), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics, European Journal of Human Genetics.
- Manson, L.E.N.; Delwig, S.J.; Drabbels, J.J.M.; Touw, D.J.; Vries, A.P.J. de; Roelen, D.L. & Guchelaar, H.J. (2023), Repurposing HLA genotype data of renal transplant patients to prevent severe drug hypersensitivity reactions, Frontiers in Genetics 14.
- Knikman, J.E.; Wilting, T.A.; Lopez-Yurda, M.; Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Nieboer, P.; Droogendijk, H.J.; Creemers, G.J.; Mandigers, C.M.P.W.; Imholz, A.L.T.; Mathijssen, R.H.J.; Portielje, J.E.A.; Valkenburg-van Iersel, L.; Vulink, A.; Poel, M.H.W. van der; Baars, A.; Swen, J.J.; Gelderblom, H.; Schellens, J.H.M.; Beijnen, J.H.; Guchelaar, H.J. & Cats, A. (2023), Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy, Journal of Clinical Oncology 41(35): 5411-+.
- Yin A., Hasselt J.G.C. van, Guchelaar H.J., Friberg L.E. & Moes D.J.A.R. (2022), Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance, Scientific Reports 12(1): 4206.
- Yin A., Hasselt J.G.C. van, Guchelaar H.J., Friberg L.E. & Moes D.J. (2022), Publisher correction: anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance, Scientific Reports 12(1): 4879 (4879).
- Manson, L.E.N.; Chan, P.C.Y.; Bohringer, S. & Guchelaar, H.J. (2022), Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions, Frontiers in Pharmacology 13.
- Nijenhuis, M.; Soree, B.; Jama, W.O.M.; Boer-Veger, N.J. de; Buunk, A.M.; Guchelaar, H.J.; Houwink, E.J.F.; Rongen, G.A.; Schaik, R.H.N. van; Swen, J.J.; Touw, D.; Weide, J. van der; Westrhenen, R. van; Deneer, V.H.M. & Risselada, A. (2022), Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate, European Journal of Human Genetics.
- Stoep, M.Y.E.C. van der; Oostenbrink, L.V.E.; Bredius, R.G.M.; Moes, D.J.A.R.; Guchelaar, H.J.; Zwaveling, J. & Lankester, A.C. (2022), Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?, Frontiers in Pharmacology 13.
- Moes, D.J.A.R.; Westerloo, D.J. van; Arend, S.M.; Swen, J.J.; Vries, A. de; Guchelaar, H.J.; Joosten, S.A.; Boer, M.G.J. de; Gelder, T. van & Paassen, J. van (2022), Towards fixed dosing of tocilizumab in ICU-admitted COVID-19 patients, Clinical Pharmacokinetics 61.
- With, M. de; Knikman, J.; Schellens, J.H.M.; Gelderblom, H.; Cats, A.; Guchelaar, H.J.; Mathijssen, R.H.J.; Swen, J.J. & Meulendijks, D. (2022), Response to "Plasma Uracil as a DPD Phenotyping Test: Pre-analytical Handling Matters", Clinical Pharmacology & Therapeutics 113(3).
- Habtemariam, H.D. & Guchelaar, H.J. (2022), The potential application of extracellular vesicles from liquid biopsies for determination of pharmacogene expression, Pharmaceuticals 15(2).
- Hulshof, E.C.; With, M. de; Man, F.M. de; Creemers, G.J.; Deiman, B.A.L.M.; Swen, J.J.; Houterman, S.; Koolen, S.L.W.; Bins, S.; Thijs, A.M.J.; Laven, M.M.J.; Hovels, A.M.; Luelmo, S.A.C.; Houtsma, D.; Shulman, K.; McLeod, H.L.; Schaik, R.H.N. van; Guchelaar, H.J.; Mathijssen, R.H.J.; Gelderblom, H. & Deenen, M.J. (2022), UGT1A1 genotype-guided dosing of irinotecan, European Journal of Cancer 162: 148-157.
- Zwart, T.C.; Metscher, E.; Boog, P.J.M. van der; Swen, J.J.; Fijter, J.W. de; Guchelaar, H.J.; Vries, A.P.J. de & Moes, D.J.A.R. (2022), Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients, British Journal of Clinical Pharmacology 88(11).
- Laar, S.A. van; Gombert-Handoko, K.B.; Groenwold, R.H.H.; Hulle, T. van der; Visser, L.E.; Houtsma, D.; Guchelaar, H.J. & Zwaveling, J. (2022), Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in the Netherlands, Frontiers in Pharmacology 13.
- Laar, S.A. van; Gombert-Handoko, K.B.; Wassenaar, S.; Kroep, J.R.; Guchelaar, H.J. & Zwaveling, J. (2022), Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients, Supportive Care in Cancer.
- Wouden, C.H. van der; Guchelaar, H.J. & Swen, J.J. (2022), Precision Medicine Using Pharmacogenomic Panel-Testing Current Status and Future Perspectives, Clinics in Laboratory Medicine 42(4): 587-602.
- Diekstra, M.H.M.; Swen, J.J.; Zanden, L.F.M. van der; Vermeulen, S.H.; , E. boven; Mathijssen, R.H.J.; Fukunaga, K.; Mushiroda, T.; Hongo, F.; Oosterwijk, E.; Cambon-Thomsen, A.; Castellano, D.; Fritsch, A.; Donas, J.G.; Rodriguez-Antona, C.; Ruijtenbeek, R.; Radu, M.T.; Eisen, T.; Junker, K.; Roessler, M.; Jaehde, U.; Miki, T.; Bohringer, S.; Kubo, M.; Kiemeney, L.A.L.M. & Guchelaar, H.J. (2022), Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 that correlate with efficacy outcomes in metastatic renal cell carcinoma patients treated with sunitinib, Cancers 14(12).
- Hulshof, E.C.; With, M. de; Creemers, G.J.; Guchelaar, H.J.; Mathijssen, R.H.; Gelderblom, H. & Deenen, M.J. (2022), Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
- Blagec, K.; Swen, J.J.; Koopmann, R.; Cheung, K.C.; Crommentuijn-van Rhenen, M.; Holsappel, I.; Konta, L.; Ott, S.; Steinberger, D.; Xu, H.; Cecchin, E.; Dolzan, V.; Davila-Fajardo, C.L.; Patrinos, G.P.; Sunder-Plassmann, G.; Turner, R.M.; Pirmohamed, M.; Guchelaar, H.J.; Samwald, M. & Ubiquitous Pharmacogenomics Consortium (2022), Pharmacogenomics decision support in the U-PGx project, PLoS ONE 17(6).
- Gordijn, R.; Wessels, W.; Kriek, E.; Nicolai, M.P.J.; Elzevier, H.W.; Visser, L.; Guchelaar, H.J. & Teichert, M. (2022), Patient reporting of sexual adverse events on an online platform for medication experiences, British Journal of Clinical Pharmacology 88(12).
- Laar, S.A. van; Kapiteijn, E.; Gombert-Handoko, K.B.; Guchelaar, H.J. & Zwaveling, J. (2022), Application of Electronic Health Record Text Mining, Cancers 14(21).
- Stoep, M.Y.E.C. van der; Bertaina, A.; Moes, D.J.A.R.; Algeri, M.; Bredius, R.G.M.; Smiers, F.J.W.; Berghuis, D.; Buddingh, E.P.; Mohseny, A.B.; Guchelaar, H.J.; Locatelli, F.; Zwaveling, J. & Lankester, A.C. (2022), Impact of treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients, Transplantation and Cellular Therapy 28(2).
- Klumpers, M.J.; Witte, W. de; Gattuso, G.; Schiavello, E.; Terenziani, M.; Massimino, M.; Gidding, C.E.M.; Vermeulen, S.H.; Driessen, C.M.; Herpen, C.M. van; Meerten, E. van; Guchelaar, H.J.; Coenen, M.J.H. & Loo, D.M.W.M. te (2022), Genome-wide analyses of nephrotoxicity in platinum-treated cancer patients identify association with genetic variant in RBMS3 and acute kidney injury, Journal of Personalized Medicine 12(6).
- Pol, K.H. van der; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Guchelaar, H.J.; Risselada, A.; Schaik, R.H.N. van; Swen, J.J.; Touw, D.; Weide, J. van der; Westrhenen, R. van; Deneer, V.H.M.; Houwink, E.J.F. & Rongen, G.A. (2022), Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and allopurinol, and MTHFR, folic acid and methotrexate, European Journal of Human Genetics.
- With, M. de; Knikman, J.; Man, F.M. de; Lunenburg, C.A.T.C.; Henricks, L.M.; Kuilenburg, A.B.P. van; Maring, J.G.; Staveren, M.C. van; Vries, N. de; Rosing, H.; Beijnen, J.H.; Pluim, D.; Modak, A.; Imholz, A.L.T.; Schaik, R.H.N. van; Schellens, J.H.M.; Gelderblom, H.; Cats, A.; Guchelaar, H.J.; Mathijssen, R.H.J.; Swen, J.J. & Meulendijks, D. (2022), Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil, Clinical Pharmacology & Therapeutics 112(1): 62-68.
- Wouden, C.H. van der; Marck, H.; Guchelaar, H.J.; Swen, J.J. & Hout, W.B. van den (2022), Cost-effectiveness of pharmacogenomics-guided prescribing to prevent gene-drug-related deaths, Frontiers in Pharmacology 13.
- Klumpers, M.J.; Brand, A.C.A.M.; Hakobjan, M.; Gattuso, G.; Schiavello, E.; Terenziani, M.; Massimino, M.; Gidding, C.E.M.; Guchelaar, H.J.; Loo, D.M.W.M. te & Coenen, M.J.H. (2022), Contribution of common and rare genetic variants in CEP72 on vincristine-induced peripheral neuropathy in brain tumour patients, British Journal of Clinical Pharmacology 88(7): 3463-3473.
- Yin, A.Y.; Hasselt, J.G.C. van; Guchelaar, H.J.; Friberg, L.E. & Moes, D.J.A.R. (2022), Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance, Scientific Reports 12(1).
- Lafeber, I.; Ruijgrok, E.J.; Guchelaar, H.J. & Schimmel, K.J.M. (2022), 3D printing of pediatric medication: the end of bad-tasting oral liquids? - A scoping review, Pharmaceutics 14(2).
- Hulshof, E.C.; Deenen, M.J.; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Risselada, A.; Rongen, G.A.P.J.M.; Schaik, R.H.N. van; Touw, D.J.; Weide, J. van der; Westrhenen, R. van; Deneer, V.H.M.; Guchelaar, H.J. & Swen, J.J. (2022), Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan, European Journal of Human Genetics.
- Koudijs, K.K.M.; Bohringer, S. & Guchelaar, H.J. (2022), Validation of transcriptome signature reversion for drug repurposing in oncology, Briefings in Bioinformatics 24(1).
- Manson, L.E.N.; Hout, W.B. van den & Guchelaar, H.J. (2022), Genotyping for HLA risk alleles to prevent drug hypersensitivity reactions, Pharmaceuticals 15(1).
- Zwart, T.C.; Bezstarosti, S.; Achini, F.R.; Reinders, M.E.J.; Schilham, M.W.; Heidt, S.; Guchelaar, H.J.; Fijter, J.W. de & Moes, D.J.A.R. (2022), Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation, British Journal of Clinical Pharmacology 89(4).
- Mosch, R. & Guchelaar, H.J. (2022), Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients, Frontiers in Immunology 13.
- Youssef, E.; Kirkdale, C.L.; Wright, D.J.; Guchelaar, H.J. & Thornley, T. (2021), Estimating the potential impact of implementing pre-emptive pharmacogenetic testing in primary care across the UK, British Journal of Clinical Pharmacology 87(7).
- Laar, S.A. van; Boer, M.G.J. de; Gombert-Handoko, K.B.; Guchelaar, H.J.; Zwaveling, J. & LUMC-Covid-19 Res grp (2021), Liver and kidney function in patients with Covid-19 treated with remdesivir, British Journal of Clinical Pharmacology 87(11).
- Matic, M.; Nijenhuis, M.; Soree, B.; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Mulder, H.; Rongen, G.A.P.J.M.; Weide, J. van der; Wilffert, B.; Swen, J.J.; Guchelaar, H.J.; Deneer, V.H.M. & Schaik, R.H.N. van (2021), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone), European Journal of Human Genetics.
- Stoep, M.Y.E.C. van der; Berghuis, D.; Bredius, R.G.M.; Buddingh, E.P.; Mohseny, A.B.; Smiers, F.J.W.; Guchelaar, H.J.; Lankester, A.C. & Zwaveling, J. (2021), Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool, Scientific Reports 11(1).
- Sanchez-Spitman, A.B.; Swen, J.J.; Dezentje, V.O.; Moes, D.J.A.R.; Gelderblom, H. & Guchelaar, H.J. (2021), Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse, Scientific Reports 11(1).
- Brouwer, J.M.J.L.; Nijenhuis, M.; Soree, B.; Guchelaar, H.J.; Swen, J.J.; Schaik, R.H.N. van; Weide, J. van der; Rongen, G.A.P.J.M.; Buunk, A.M.; Boer-Veger, N.J. de; Houwink, E.J.F.; Westrhenen, R. van; Wilffert, B.; Deneer, V.H.M. & Mulder, H. (2021), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs, European Journal of Human Genetics.
- Ciccolini, J.; Milano, G. & Guchelaar, H.J. (2021), Detecting DPD deficiency: when perfect is the enemy of good.
- Tafazoli, A.; Guchelaar, H.J.; Miltyk, W.; Kretowski, A.J. & Swen, J.J. (2021), Applying next-generation sequencing platforms for pharmacogenomic testing in clinical practice, Frontiers in Pharmacology 12.
- Lee, M. van der; Guchelaar, H.J. & Swen, J.J. (2021), Substrate specificity of CYP2D6 genetic variants, Pharmacogenomics 22(16): 1081-1089.
- Zwart, T.C.; Guchelaar, H.J.; Boog, P.J.M. van der; Swen, J.J.; Gelder, T. van; Fijter, J.W. de & Moes, D.J.A.R. (2021), Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation, Drug Discovery Today 26(11): 2527-2546.
- Lee, M. van der; Rowell, W.J.; Menafra, R.; Guchelaar, H.J.; Swen, J.J. & Anvar, S.Y. (2021), Application of long-read sequencing to elucidate complex pharmacogenomic regions, Pharmacogenomics Journal 22.
- Daele, R. van; Debaveye, Y.; Vos, R.; Bleyenbergh, P. van; Bruggemann, R.J.; Dreesen, E.; Elkayal, O.; Guchelaar, H.J.; Vermeersch, P.; Lagrou, K. & Spriet, I. (2021), Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics, Mycoses.
- Visser, C.D.; Linthorst, J.M.; Kuipers, E.; Sont, J.K.; Lacroix, J.P.W.; Guchelaar, H.J. & Teichert, M. (2021), Respiratory Adherence Care Enhancer Questionnaire: Identifying Self-Management Barriers of Inhalation Corticosteroids in Asthma, Frontiers in Pharmacology 12.
- Lafeber, I.; Tichem, J.M.; Ouwerkerk, N.; Unen, A.D. van; Uitert, J.J.D. van; Bijleveld-Olierook, H.C.M.; Kweekel, D.M.; Zaal, W.M.; Brun, P.P.H. le; Guchelaar, H.J. & Schimmel, K.J.M. (2021), 3D printed furosemide and sildenafil tablets, International Journal of Pharmaceutics 603.
- Gordijn, R.; Nicolai, M.P.J.; Elzevier, H.W.; Guchelaar, H.J. & Teichert, M. (2021), An estimation of patients at potential risk for drug-induced sexual dysfunction using pharmacy dispensing data, Family Practice 38(3): 292-298.
- Lee, M. van der; Allard, W.G.; Vossen, R.H.A.M.; Baak-Pablo, R.F.; Menafra, R.; Deiman, B.A.L.M.; Deenen, M.J.; Neven, P.; Johansson, I.; Gastaldello, S.; Ingelman-Sundberg, M.; Guchelaar, H.J.; Swen, J.J. & Anvar, S.Y. (2021), Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data, Science Translational Medicine 13(603).
- Gordijn, R.; Teichert, M.; Nicolai, M.P.J.; Elzevier, H.W.; Guchelaar, H.J. & Hughes, C.M. (2021), Learning from consultations conducted by community pharmacists in Northern Ireland for nonprescription sildenafil, Sexual Medicine 9(6).
- Houtsma, D.; Groot, S. de; Baak-Pablo, R.; Kranenbarg, E.M.K.; Seynaeve, C.M.; Velde, C.J.H. van de; Bohringer, S.; Kroep, J.R.; Guchelaar, H.J. & Gelderblom, H. (2021), The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival, Scientific Reports 11(1).
- Zwart, T.C.; Vries, A.P.J. de; Engbers, A.G.J.; Dam, R.E.; Boog, P.J.M. van der; Swen, J.J.; Keizer, R.J.; Dalton, R.N.; Guchelaar, H.J.; Fijter, J.W. de & Moes, D.J.A.R. (2021), Model-based estimation of iohexol plasma clearance for pragmatic renal function determination in the renal transplantation setting, Clinical Pharmacokinetics 60.
- Lee, M. van der; Kriek, M.; Guchelaar, H.J. & Swen, J.J. (2020), Technologies for pharmacogenomics: a review, Genes 11(12).
- Hulshof, E.C.; Deenen, M.J.; Guchelaar, H.J. & Gelderblom, H. (2020), Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: ready for prime time, European Journal of Cancer 141: 9-20.
- Caudle, K.E.; Sangkuhl, K.; Whirl-Carrillo, M.; Swen, J.J.; Haidar, C.E.; Klein, T.E.; Gammal, R.S.; Relling, M.V.; Scott, S.A.; Hertz, D.L.; Guchelaar, H.J. & Gaedigk, A. (2020), Standardizing CYP2D6 genotype to phenotype translation, Clinical and Translational Science 13(1): 116-124.
- Wouden, C.H. van der; Bohringer, S.; Cecchin, E.; Cheung, K.C.; Davila-Fajardo, C.L.; Deneer, V.H.M.; Dolzan, V.; Ingelman-Sundberg, M.; Jonsson, S.; Karlsson, M.O.; Kriek, M.; Mitropoulou, C.; Patrinos, G.P.; Pirmohamed, M.; Rial-Sebbag, E.; Samwald, M.; Schwab, M.; Steinberger, D.; Stingl, J.; Sunder-Plassmann, G.; Toffoli, G.; Turner, R.M.; Rhenen, M.H. van; Zwet, E. van; Swen, J.J.; Guchelaar, H.J. & Ubiquitous Pharmacogenomics Consor (2020), Generating evidence for precision medicine, Pharmacogenetics and Genomics 30(6): 131-144.
- Zwart, T.C.; Moes, D.J.A.R.; Boog, P.J.M. van der; Erp, N.P. van; Fijter, J.W. de; Guchelaar, H.J.; Keizer, R.J. & Heine, R. ter (2020), Model-informed precision dosing of everolimus, Clinical Pharmacokinetics 60.
- Yin, A.Y.; Ettaieb, M.H.T.; Swen, J.J.; Deun, L. van; Kerkhofs, T.M.A.; Straaten, R.J.H.M. van der; Corssmit, E.P.M.; Gelderblom, H.; Kerstens, M.N.; Feelders, R.A.; Eekhoff, M.; Timmers, H.J.L.M.; D'Avolio, A.; Cusato, J.; Guchelaar, H.J.; Haak, H.R. & Moes, D.J.A.R. (2020), Population pharmacokinetic and pharmacogenetic analysis of mitotane in patients with adrenocortical carcinoma, Clinical Pharmacokinetics 60.
- Hulshof, E.C.; Lurvink, R.J.; Caserta, N.; Hingh, I.H.J.T. de; Wezel, T. van; Bohringer, S.; Swen, J.J.; Gelderblom, H.; Guchelaar, H.J. & Deenen, M.J. (2020), Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases, European Journal of Surgical Oncology 46(10): 1925-1931.
- Hulshof, E.C.; Lim, L.; Hingh, I.H.J.T. de; Gelderblom, H.; Guchelaar, H.J. & Deenen, M.J. (2020), Genetic variants in DNA repair pathways as potential biomarkers in predicting treatment outcome of intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: a systematic review, Frontiers in Pharmacology 11.
- Manson, L.E.N.; Swen, J.J. & Guchelaar, H.J. (2020), Diagnostic test criteria for HLA genotyping to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG guidelines, Frontiers in Pharmacology 11.
- Klomp, S.D.; Manson, M.L.; Guchelaar, H.J. & Swen, J.J. (2020), Phenoconversion of cytochrome P450 metabolism: a systematic review, Journal of Clinical Medicine 9(9).
- Wouden, C.H. van der; Paasman, E.; Teichert, M.; Crone, M.R.; Guchelaar, H.J. & Swen, J.J. (2020), Assessing the implementation of pharmacogenomic panel-testing in primary care in the Netherlands utilizing a theoretical framework, Journal of Clinical Medicine 9(3).
- Hurkmans, E.G.E.; Klumpers, M.J.; Vermeulen, S.H.; Hagleitner, M.M.; Flucke, U.; Schreuder, H.W.B.; Gelderblom, H.; Bras, J.; Guchelaar, H.J.; Coenen, M.J.H. & Loo, D.M.W.M. te (2020), Analysis of drug metabolizing gene panel in osteosarcoma patients identifies association between variants inSULT1E1, CYP2B6 and CYP4F8 and methotrexate levels and toxicities, Frontiers in Pharmacology 11.
- Lunenburg, C.A.T.C.; Wouden, C.H. van der; Nijenhuis, M.; Crommentuijn-van Rhenen, M.H.; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Mulder, H.; Rongen, G.A.; Schaik, R.H.N. van; Weide, J. van der; Wilffert, B.; Deneer, V.H.M.; Swen, J.J. & Guchelaar, H.J. (2020), Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines, European Journal of Human Genetics 28(4): 508-517.
- Eektimmerman, F.; Swen, J.J.; Madhar, M.B.; Allaart, C.F. & Guchelaar, H.J. (2020), Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review, Pharmacogenomics Journal 20(2): 159-168.
- Laar, S.A. van; Gombert-Handoko, K.B.; Guchelaar, H.J. & Zwaveling, J. (2020), An electronic health record text mining tool to collect real-world drug treatment outcomes, Clinical Pharmacology & Therapeutics 108(3): 644-652.
- Sanchez-Spitman, A.B.; Moes, D.J.A.R.; Swen, J.J.; Dezentj?, V.O.; Lambrechts, D.; Neven, P.; Gelderblom, H. & Guchelaar, H.J. (2020), Exposure-response analysis of endoxifen serum concentrations in early-breast cancer, Cancer Chemotherapy and Pharmacology 85(6): 1141-1152.
- Knikman, J.E.; Gelderblom, H.; Beijnen, J.H.; Cats, A.; Guchelaar, H.J. & Henricks, L.M. (2020), Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity, Clinical Pharmacology & Therapeutics 109(3).
- Knikman, J.E.; Rosing, H.; Guchelaar, H.J.; Cats, A. & Beijnen, J.H. (2020), A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices, Biomedical Chromatography 34(1).
- Wouden, C.H. van der; Rhenen, M.H. van; Jama, W.O.M.; Ingelman-Sundberg, M.; Lauschke, V.M.; Konta, L.; Schwab, M.; Swen, J.J. & Guchelaar, H.J. (2020), One non-believer: response to "Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing".
- Ubels, J.; Schaefers, T.; Punt, C.; Guchelaar, H.J. & Ridder, J. de (2020), RAINFOREST: a random forest approach to predict treatment benefit in data from (failed) clinical drug trials, Bioinformatics 36: I601-I609.
- Bank, P.C.D.; Swen, J.J. & Guchelaar, H.J. (2019), Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands, BMC Medicine 17.
- Henricks, L.M.; Lunenburg, C.A.T.C.; Cats, A.; Mathijssen, R.H.J.; Guchelaar, H.J. & Schellens, J.H.M. (2019), DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how? reply, Lancet Oncology 20(2): E67-E67.
- Lunenburg, C.A.T.C.; Guchelaar, H.J.; Schaik, R.H.N. van; Neumaier, M. & Swen, J.J. (2019), Confirmation practice in pharmacogenetic testing; how good is good enough?, Clinica Chimica Acta 490: 77-80.
- Sanchez-Spitman, A.B.; Swen, J.J.; Dezentje, V.O.; Moes, D.J.A.R.; Gelderblom, H. & Guchelaar, H.J. (2019), Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen, Expert Review of Clinical Pharmacology 12(6): 523-536.
- Spiliopoulou, A.; Colombo, M.; Plant, D.; Nair, N.; Cui, J.; Coenen, M.J.H.; Ikari, K.; Yamanaka, H.; Saevarsdottir, S.; Padyukov, L.; Bridges, S.L.; Kimberly, R.P.; Okada, Y.; Riel, P.L.C.M. van; Wolbink, G.; Horst-Bruinsma, I.E. van der; Vries, N. de; Tak, P.P.; Ohmura, K.; Canhao, H.; Guchelaar, H.J.; Huizinga, T.W.J.; Criswell, L.A.; Raychaudhuri, S.; Weinblatt, M.E.; Wilson, A.G.; Mariette, X.; Isaacs, J.D.; Morgan, A.W.; Pitzalis, C.; Barton, A. & McKeigue, P. (2019), Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39, Annals of the Rheumatic Diseases 78(8): 1055-1061.
- Gordijn, R.; Teichert, M.; Nicolai, M.P.J.; Elzevier, H.W. & Guchelaar, H.J. (2019), Adverse drug reactions on sexual functioning: a systematic overview, Drug Discovery Today 24(3): 890-897.
- Lee, M. van der; Allard, W.G.; Bollen, S.; Santen, G.W.E.; Ruivenkamp, C.A.L.; Hoffer, M.J.V.; Kriek, M.; Guchelaar, H.J.; Anvar, S.Y. & Swen, J.J. (2019), Repurposing of Diagnostic Whole Exome Sequencing Data of 1,583 Individuals for Clinical Pharmacogenetics, Clinical Pharmacology and Therapeutics.
- Bank, P.C.D.; Swen, J.J.; Schaap, R.D.; Klootwijk, D.B.; Baak-Pablo, R. & Guchelaar, H.J. (2019), A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care, European Journal of Human Genetics 27(10): 1532-1541.
- Yin, A.Y.; Moes, D.J.A.R.; Hasselt, J.G.C. van; Swen, J.J. & Guchelaar, H.J. (2019), A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors, CPT: Pharmacometrics and Systems Pharmacology 8(10): 720-737.
- Wouden, C.H. van der; Rhenen, M.H. van; Jama, W.O.M.; Ingelman-Sundberg, M.; Lauschke, V.M.; Konta, L.; Schwab, M.; Swen, J.J. & Guchelaar, H.J. (2019), Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing, Clinical Pharmacology and Therapeutics 106(4): 866-873.
- Verboom, M.C.; Kloth, J.S.L.; Swen, J.J.; Sleijfer, S.; Reyners, A.K.L.; Steeghs, N.; Mathijssen, R.H.J.; Gelderblom, H. & Guchelaar, H.J. (2019), Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors, Pharmacogenomics Journal 19(5): 473-479.
- Sluiter, R.L.; Marrewijk, C. van; Jong, D. de; Scheffer, H.; Guchelaar, H.J.; Derijks, L.; Wong, D.R.; Hooymans, P.; Vermeulen, S.H.; Verbeek, A.L.M.; Franke, B.; Wilt, G.J. van der; Kievit, W. & Coenen, M.J.H. (2019), Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease, Journal of Crohn's and Colitis 13(7): 838-845.
- Stoep, M.Y.E.C. van der; Zwaveling, J.; Bertaina, A.; Locatelli, F.; Guchelaar, H.J.; Lankester, A.C. & Moes, D.J.A.R. (2019), Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation, British Journal of Clinical Pharmacology 85(9): 2033-2044.
- Wouden, C.H. van der; Bank, P.C.D.; Ozokcu, K.; Swen, J.J. & Guchelaar, H.J. (2019), Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact, Genes 10(6).
- Guchelaar, H.J.; Sanchez-Spitman, A.; Dezentje, V.; Bohringer, S.; Swen, J.; Neven, P. & Gelderblom, H. (2019), Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM Reply, Journal of Clinical Oncology 37(22): 1984-+.
- Sanchez-Spitman, A.; Dezentje, V.; Swen, J.; Moes, D.J.A.R.; Bohringer, S.; Batman, E.; Druten, E. van; Smorenburg, C.; Bochove, A. van; Zeillemaker, A.; Jongen, L.; , M. los; Neven, P.; Gelderblom, H. & Guchelaar, H.J. (2019), Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study, Journal of Clinical Oncology 37(8): 636-+.
- Koudijs, K.K.M.; Scheltinga, A.G.T.T. van; Bohringer, S.; Schimmel, K.J.M. & Guchelaar, H.J. (2019), The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples, Scientific Reports 9.
- Koudijs, K.K.M.; Scheltinga, A.G.T.T. van; Bohringer, S.; Schimmel, K.J.M. & Guchelaar, H.J. (2019), Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology, Cancer Journal 25(2): 116-120.
- Eektimmerman, F.; Allaart, C.F.; Hazes, J.M.W.; Broeder, A.A. den; Fransen, J.; Swen, J.J. & Guchelaar, H.J. (2019), Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients, Pharmacogenomics 20(2): 85-93.
- Au, L.; Koudijs, K.K.M.; Scheltinga, A.G.T.T. van & Guchelaar, H.J. (2019), Non-Cancer Drug Repurposing Candidates for Renal Cell Carcinoma, Cancer Journal 25(2): 147-148.
- Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J. & Schellens, J.H.M. (2019), A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy, European Journal of Cancer 107: 60-67.
- Lunenburg, C.A.T.C.; Henricks, L.M.; Kuilenburg, A.B.P. van; Mathijssen, R.H.J.; Schellens, J.H.M.; Gelderblom, H.; Guchelaar, H.J. & Swen, J.J. (2018), Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants, Genes 9(12).
- Henricks, L.M.; Jacobs, B.A.W.; Meulendijks, D.; Pluim, D.; Broek, D. van den; Vries, N. de; Rosing, H.; Beijnen, J.H.; Huitema, A.D.R.; Guchelaar, H.J.; Cats, A. & Schellens, J.H.M. (2018), Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers, British Journal of Clinical Pharmacology 84(12): 2761-2769.
- Baas, J.; Krens, L.; Bohringer, S.; Mol, L.; Punt, C.; Guchelaar, H.J. & Gelderblom, H. (2018), Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab, PLoS ONE 13(12).
- Lunenburg, C.A.T.C.; Henricks, L.M.; Dreussi, E.; Peters, F.P.; Fiocco, M.; Meulendijks, D.; Toffoli, G.; Guchelaar, H.J.; Swen, J.J.; Cecchin, E.; Schellens, J.H.M. & Gelderblom, H. (2018), Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers, European Journal of Cancer 104: 210-218.
- Zwart, T.C.; Gokoel, S.R.M.; Boog, P.J.M. van der; Fijter, J. de; Kweekel, D.M.; Swen, J.J.; Guchelaar, H.J. & Moes, D.J.A.R. (2018), Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device, British Journal of Clinical Pharmacology 84(12): 2889-2902.
- Eektimmerman, F.; Swen, J.J.; Bohringer, S.; Aslibekyan, S.; Allaart, C.F. & Guchelaar, H.J. (2018), SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients, Pharmacogenomics 19(7): 613-619.
- Wilde, S. de; Jong, M.G.H. de; Lipka, A.F.; Guchelaar, H.J. & Schimmel, K.J.M. (2018), The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome, European Journal of Pharmaceutical Sciences 114: 24-29.
- Broekman, M.M.T.J.; Wong, D.R.; Wanten, G.J.A.; Roelofs, H.M.; Marrewijk, C.J. van; Klungel, O.H.; Verbeek, A.L.M.; Hooymans, P.M.; Guchelaar, H.J.; Scheffer, H.; Derijks, L.J.J.; Coenen, M.J.H.; Jong, D.J. de & TOPIC Recruitment Team (2018), The glutathione transferase Mu null genotype leads to lower 6-MMPR levels in patients treated with azathioprine but not with mercaptopurine, Pharmacogenomics Journal 18(1): 160-166.
- Neven, P.; Jongen, L.; Lintermans, A.; Asten, K. van; Blomme, C.; Lambrechts, D.; Poppe, A.; Wildiers, H.; Dieudonne, A.S.; Brouckaert, O.; Decloedt, J.; Berteloot, P.; Verhoeven, D.; Joerger, M.; Vuylsteke, P.; Wynendaele, W.; Casteels, M.; Huffel, S. van; Lybaert, W.; Ginderachter, J. van; Paridaens, R.; Vergote, I.; Dezentje, V.O.; Calster, B. van & Guchelaar, H.J. (2018), Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial, Clinical Cancer Research 24(10): 2312-2318.
- Lam, S.W.; Noort, V. van der; Straaten, T. van der; Honkoop, A.H.; Peters, G.J.; Guchelaar, H.J. & , E. boven (2018), Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer, Pharmacological Research 128: 122-129.
- Guchelaar, H.J. (2018), Pharmacogenomics, a novel section in the European Journal of Human Genetics, European Journal of Human Genetics 26(10): 1399-1400.
- Bank, P.C.D.; Swen, J.J. & Guchelaar, H.J. (2018), A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands, Pharmacogenomics 19(4): 311-319.
- Goetz, M.P.; Sangkuhl, K.; Guchelaar, H.J.; Schwab, M.; Province, M.; Whirl-Carrillo, M.; Symmans, W.F.; McLeod, H.L.; Ratain, M.J.; Zembutsu, H.; Gaedigk, A.; Schaik, R.H. van; Ingle, J.N.; Caudle, K.E. & Klein, T.E. (2018), Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy, Clinical Pharmacology and Therapeutics 103(5): 770-777.
- Liu, X.Y.; Swen, J.J.; Diekstra, M.H.M.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Vermeulen, S.H.; Oosterwijk, E.; Junker, K.; Roessler, M.; Alexiusdottir, K.; Sverrisdottir, A.; Radu, M.T.; Ambert, V.; Eisen, T.; Warren, A.; Rodriguez-Antona, C.; Garcia-Donas, J.; Bohringer, S.; Koudijs, K.K.M.; Kiemeney, L.A.L.M.; Rini, B.I. & Guchelaar, H.J. (2018), A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma, Clinical Cancer Research 24(10): 2350-2356.
- Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J. & Schellens, J.H.M. (2018), DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis, Lancet Oncology 19(11): 1459-1467.
- Swen, J.J.; Nijenhuis, M.; Rhenen, M. van; Boer-Veger, N.J. de; Buunk, A.M.; Houwink, E.J.F.; Mulder, H.; Rongen, G.A.; Schaik, R.H.N. van; Weide, J. van der; Wilffert, B.; Deneer, V.H.M.; Guchelaar, H.J. & Royal Dutch Pharmacists Assoc KNMP (2018), Pharmacogenetic Information in Clinical Guidelines: The European Perspective, Clinical Pharmacology and Therapeutics 103(5): 795-801.
- Kloth, J.S.L.; Verboom, M.C.; Swen, J.J.; Straaten, T. van der; Sleijfer, S.; Reyners, A.K.L.; Steeghs, N.; Gelderblom, H.; Guchelaar, H.J. & Mathijssen, R.H.J. (2018), Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib, Pharmacogenomics Journal 18(1): 49-55.
- Coppens, D.G.M.; Wilde, S. de; Guchelaar, H.J.; Bruin, M.L. de; Leufkens, H.G.M.; Meij, P. & Hoekman, J. (2018), A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making, Cytotherapy 20(6): 769-778.
- Koudijs, K.K.M.; Scheltinga, A.G.T.T. van; Bohringer, S.; Schimmel, K.J.M. & Guchelaar, H.J. (2018), Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression, Scientific Reports 8.
- Broekman, M.M.T.J.; Coenen, M.J.H.; Wanten, G.J.; Marrewijk, C.J. van; Kievit, W.; Klungel, O.H.; Verbeek, A.L.M.; Wong, D.R.; Hooymans, P.M.; Guchelaar, H.J.; Scheffer, H.; Derijks, L.J.J.; Bouvy, M.L. & Jong, D.J. de (2018), Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases, European Journal of Gastroenterology and Hepatology 30(2): 167-173.
- Blagec, K.; Koopmann, R.; Crommentuijn-van Rhenen, M.; Holsappel, I.; Wouden, C.H. van der; Konta, L.; Xu, H.; Steinberger, D.; Just, E.; Swen, J.J.; Guchelaar, H.J. & Samwald, M. (2018), Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project, Journal of the American Medical Informatics Association 25(7): 893-898.
- Ketzer, S.; Schimmel, K.; Koopman, M. & Guchelaar, H.J. (2018), Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer, Clinical Pharmacokinetics 57(4): 455-473.
- Bank, P.C.D.; Caudle, K.E.; Swen, J.J.; Gammal, R.S.; Whirl-Carrillo, M.; Klein, T.E.; Relling, M.V. & Guchelaar, H.J. (2018), Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group, Clinical Pharmacology and Therapeutics 103(4): 599-618.
- Wilde, S. de; Coppens, D.G.M.; Hoekman, J.; Bruin, M.L. de; Leufkens, H.G.M.; Guchelaar, H.J. & Meij, P. (2018), EU decision-making for marketing authorization of advanced therapy medicinal products: a case study, Drug Discovery Today 23(7): 1328-1333.
- Sanchez-Spitman, A.B.; Dezentje, V.O.; Swen, J.J.; Moes, D.J.A.R.; Gelderblom, H. & Guchelaar, H.J. (2018), Genetic polymorphisms of 3-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy, Breast Cancer Research and Treatment 172(2): 401-411.
- Heine, R. ter; Erp, N.P. van; Guchelaar, H.J.; Fijter, J.W. de; Reinders, M.E.J.; Herpen, C.M. van; Burger, D.M. & Moes, D.J.A.R. (2018), A pharmacological rationale for improved everolimus dosing in oncology and transplant patients, British Journal of Clinical Pharmacology 84(7): 1575-1586.
- Wilde, S. de; Jong, M.G.H. de; Brun, P.P.H. le; Guchelaar, H.J. & Schimmel, K.J.M. (2018), Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety, Pharmacoepidemiology and Drug Safety 27(1): 3-8.
- Krens, L.L.; Baas, J.M.; Guchelaar, H.J. & Gelderblom, H. (2018), Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease, Cancer Chemotherapy and Pharmacology 81(1): 179-182.
- Beusekom M.M. van, Land-Zandstra A.M., Bos M.J.W., Broek J.M. van den & Guchelaar H.J. (2017), Pharmaceutical pictograms for low-literate patients: Understanding, risk of false confidence, and evidence-based design strategies, Patient Education and Counseling 100(5): 966-973.
- Lunenburg, C.A.T.C.; Swen, J.J.; Guchelaar, H.J. & Gelderblom, H. (2017), Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil, Journal of Gastrointestinal Cancer 48(1): 117-118.
- Just, K.S.; Steffens, M.; Swen, J.J.; Patrinos, G.P.; Guchelaar, H.J. & Stingl, J.C. (2017), Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx), European Journal of Clinical Pharmacology 73(10): 1247-1252.
- Broekman, M.M.T.J.; Coenen, M.J.H.; Wanten, G.J.; Marrewijk, C.J. van; Klungel, O.H.; Verbeek, A.L.M.; Hooymans, P.M.; Guchelaar, H.J.; Scheffer, H.; Derijks, L.J.J.; Wong, D.R. & Jong, D.J. de (2017), Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype, Alimentary Pharmacology and Therapeutics 46(10): 953-963.
- Liu, X.Y.; Fiocco, M.; Swen, J.J. & Guchelaar, H.J. (2017), Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis, Acta Oncologica 56(4): 582-589.
- Zanden, L.F.M. van der; Vermeulen, S.H.; Oskarsdottir, A.; Maurits, J.S.F.; Diekstra, M.H.M.; Ambert, V.; Cambon-Thomsen, A.; Castellano, D.; Fritsch, A.; Donas, J.G.; Troyas, R.G.; Guchelaar, H.J.; Hartmann, A.; Hulsbergen-van de Kaa, C.; Jaehde, U.; Junker, K.; Martinez-Cardus, A.; Masson, G.; Oosterwijk-Wakka, J.; Radu, M.T.; Rafnar, T.; Rodriguez-Antona, C.; Roessler, M.; Ruijtenbeek, R.; Stefansson, K.; Warren, A.; Wessels, L.; Eisen, T.; Kiemeney, L.A.L.M. & Oosterwijk, E. (2017), Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity, Urologic Oncology: Seminars and Original Investigations 35(8).
- Wong, D.R.; Coenen, M.J.H.; Vermeulen, S.H.; Derijks, L.J.J.; Marrewijk, C.J. van; Klungel, O.H.; Scheffer, H.; Franke, B.; Guchelaar, H.J.; Jong, D.J. de; Engels, L.G.J.B.; Verbeek, A.L.M. & Hooymans, P.M. (2017), Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease, Journal of Crohn's and Colitis 11(2): 175-184.
- Apellaniz-Ruiz, M.; Diekstra, M.H.; Roldan, J.M.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Swen, J.J.; Bohringer, S.; Garcia-Donas, J.; Rini, B.I.; Guchelaar, H.J. & Rodriguez-Antona, C. (2017), Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma, Pharmacogenetics and Genomics 27(6): 227-231.
- Schneider, T.C.; Wit, D. de; Links, T.P.; Erp, N.P. van; Hoeven, J.J.M. van der; Gelderblom, H.; Roozen, I.C.F.M.; Bos, M.; Corver, W.E.; Wezel, T. van; Smit, J.W.A.; Morreau, H.; Guchelaar, H.J. & Kapiteijn, E. (2017), Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial, Journal of Clinical Endocrinology and Metabolism 102(2): 698-707.
- Buermans, H.P.J.; Vossen, R.H.A.M.; Anvar, S.Y.; Allard, W.G.; Guchelaar, H.J.; White, S.J.; Dunnen, J.T. den; Swen, J.J. & Straaten, T. van der (2017), Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing, Human Mutation 38(3): 310-316.
- Wouden, C.H. van der; Cambon-Thomsen, A.; Cecchin, E.; Cheung, K.C.; Davila-Fajardo, C.L.; Deneer, V.H.; Dolzan, V.; Ingelman-Sundberg, M.; Jonsson, S.; Karlsson, M.O.; Kriek, M.; Mitropoulou, C.; Patrinos, G.P.; Pirmohamed, M.; Samwald, M.; Schaeffeler, E.; Schwab, M.; Steinberger, D.; Stingl, J.; Sunder-Plassmann, G.; Toffoli, G.; Turner, R.M.; Rhenen, M. van; Swen, J.J.; Guchelaar, H.J. & Ubiquitous Pharmacogenomics Consor (2017), Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium, Clinical Pharmacology and Therapeutics 101(3): 341-358.
- Diekstra, M.H.; Fritsch, A.; Kanefendt, F.; Swen, J.J.; Moes, D.J.A.R.; Sorgel, F.; Kinzig, M.; Stelzer, C.; Schindele, D.; Gauler, T.; Hauser, S.; Houtsma, D.; Roessler, M.; Moritz, B.; Mross, K.; Bergmann, L.; Oosterwijk, E.; Kiemeney, L.A.; Guchelaar, H.J. & Jaehde, U. (2017), Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer, CPT: Pharmacometrics and Systems Pharmacology 6(9): 604-613.
- Wilde, S. de; Guchelaar, H.J.; Zandvliet, M.L. & Meij, P. (2017), Understanding clinical development of chimeric antigen receptor T cell therapies, Cytotherapy 19(6): 703-709.
- Broekman, M.M.T.J.; Coenen, M.J.H.; Marrewijk, C.J. van; Wanten, G.J.A.; Wong, D.R.; Verbeek, A.L.M.; Klungel, O.H.; Hooymans, P.M.; Guchelaar, H.J.; Scheffer, H.; Derijks, L.J.J.; Jong, D.J. de & TOPIC Recruitment Team (2017), More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing, Inflammatory Bowel Diseases 23(10): 1873-1881.
- Eektimmerman, F.; Swen, J.J.; Bohringer, S.; Huizinga, T.W.J.; Kooloos, W.M.; Allaart, C.F. & Guchelaar, H.J. (2017), Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis, Pharmacogenomics 18(10): 945-953.
- Beusekom, M.M. van; Land-Zandstra, A.M.; Bos, M.J.W.; Broek, J.M. van den & Guchelaar, H.J. (2017), Pharmaceutical pictograms for low-literate patients: Understanding, risk of false confidence, and evidence-based design strategies, Patient Education and Counseling 100(5): 966-973.
- Diekstra, M.; Belaustegui, A.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.; Garcia-Donas, J.; Rodriguez-Antona, C.; Rini, B.I. & Guchelaar, H.J. (2017), Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma, Pharmacogenomics Journal 17(1): 42-46.
- Manson, L.E.N.; Wouden, C.H. van der; Swen, J.J. & Guchelaar, H.J. (2017), The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen, Pharmacogenomics 18(11): 1041-1045.
- Cecchin, E.; Roncato, R.; Guchelaar, H.J.; Toffoli, G. & Ubiquitous Pharmacogenomics Consor (2017), Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice, Current Pharmaceutical Biotechnology 18(3): 204-209.
- Guglieri-Lopez, B.; Perez-Pitarch, A.; Moes, D.J.A.R.; Porta-Oltra, B.; Climente-Marti, M.; Guchelaar, H.J. & Merino-Sanjuan, M. (2017), Population pharmacokinetics of lenalidomide in multiple myeloma patients, Cancer Chemotherapy and Pharmacology 79(1): 189-200.
- Liu, X.Y.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B.I. & Guchelaar, H.J. (2017), Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients, Oncotarget 8(1): 1204-1212.
- Diekstra, M.H.; Liu, X.Y.; Swen, J.J. & Guchelaar, H.J. (2017), What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?, Pharmacogenomics 18(1): 1-4.
- Wong, D.R.; Coenen, M.J.H.; Derijks, L.J.J.; Vermeulen, S.H.; Marrewijk, C.J. van; Klungel, O.H.; Scheffer, H.; Franke, B.; Guchelaar, H.J.; Jong, D.J. de; Engels, L.G.J.B.; Verbeek, A.L.M.; Hooymans, P.M. & TOPIC Recruitment Team (2017), Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease, Alimentary Pharmacology and Therapeutics 45(3): 391-402.
- Stoep, M.Y.E.C. van der; Bertaina, A.; Brink, M.H. ten; Bredius, R.G.; Smiers, F.J.; Wanders, D.C.M.; Moes, D.J.A.R.; Locatelli, F.; Guchelaar, H.J.; Zwaveling, J. & Lankester, A.C. (2017), High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study, British Journal of Haematology 179(5): 772-780.
- Verboom, M.C.; Kloth, J.S.L.; Swen, J.J.; Straaten, T. van der; Bovee, J.V.M.G.; Sleijfer, S.; Reyners, A.K.L.; Mathijssen, R.H.J.; Guchelaar, H.J.; Steeghs, N. & Gelderblom, H. (2017), Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib, European Journal of Cancer 86: 226-232.
- Spitman, A.B.; Moes, D.J.A.R.; Gelderblom, H.; Dezentje, V.O.; Swen, J. & Guchelaar, H.J. (2017), Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism, European Journal of Clinical Pharmacology 73(12): 1589-1598.
- Bank, P.C.D.; Swen, J.J. & Guchelaar, H.J. (2017), A nationwide survey of pharmacists' perception of pharmacogenetics in the context of a clinical decision support system containing pharmacogenetics dosing recommendations, Pharmacogenomics 18(3): 215-225.
- Sanchez-Spitman, A.B.; Moes, D.J.A.R.; Gelderblom, H.; Dezentje, V.O.; Swen, J.J. & Guchelaar, H.J. (2017), The effect of rs5758550 on CYP2D6(star)2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen, Pharmacogenomics 18(12): 1125-1132.
- Auffray, C.; Balling, R.; Barroso, I.; Bencze, L.; Benson, M.; Bergeron, J.; Bernal-Delgado, E.; Blomberg, N.; Bock, C.; Conesa, A.; Signore, S. del; Delogne, C.; Devilee, P.; Meglio, A. di; Eijkemans, M.; Flicek, P.; Graf, N.; Grimm, V.; Guchelaar, H.J.; Guo, Y.K.; Gut, I.G.; Hanbury, A.; Hanif, S.; Hilgers, R.D.; Honrado, A.; Hose, D.R.; Houwing-Duistermaat, J.; Hubbard, T.; Janacek, S.H.; Karanikas, H.; Kievits, T.; Kohler, M.; Kremer, A.; Lanfear, J.; Lengauer, T.; Maes, E.; Meert, T.; Muller, W.; Nickel, D.; Oledzki, P.; Pedersen, B.; Petkovic, M.; Pliakos, K.; Rattray, M.; Mas, J.R.I.; Schneider, R.; Sengstag, T.; Serra-Picamal, X.; Spek, W.; Vaas, L.A.I.; Batenburg, O. van; Vandelaer, M.; Varnai, P.; Villoslada, P.; Vizcaino, J.A.; Wubbe, J.P.M. & Zanetti, G. (2016), Making sense of big data in health research: towards an EU action plan (vol 8, pg 71, 2016), Genome Medicine 8.
- Vos, H.I.; Guchelaar, H.J.; Gelderblom, H.; Bont, E.S.J.M. de; Kremer, L.C.M.; Naber, A.M.; Hakobjan, M.H.; Graaf, W.T.A. van der; Coenen, M.J.H. & Loo, D.M.W.M. te (2016), Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma, Pharmacogenetics and Genomics 26(5): 243-247.
- Auffray, C.; Balling, R.; Barroso, I.; Bencze, L.; Benson, M.; Bergeron, J.; Bernal-Delgado, E.; Blomberg, N.; Bock, C.; Conesa, A.; Signore, S. del; Delogne, C.; Devilee, P.; Meglio, A. di; Eijkemans, M.; Flicek, P.; Graf, N.; Grimm, V.; Guchelaar, H.J.; Guo, Y.K.; Gut, I.G.; Hanbury, A.; Hanif, S.; Hilgers, R.D.; Honrado, A.; Hose, D.R.; Houwing-Duistermaat, J.; Hubbard, T.; Janacek, S.H.; Karanikas, H.; Kievits, T.; Kohler, M.; Kremer, A.; Lanfear, J.; Lengauer, T.; Maes, E.; Meert, T.; Muller, W.; Nickel, D.; Oledzki, P.; Pedersen, B.; Petkovic, M.; Pliakos, K.; Rattray, M.; Mas, J.R.I.; Schneider, R.; Sengstag, T.; Serra-Picamal, X.; Spek, W.; Vaas, L.A.I.; Batenburg, O. van; Vandelaer, M.; Varnai, P.; Villoslada, P.; Vizcaino, J.A.; Wubbe, J.P.M. & Zanetti, G. (2016), Making sense of big data in health research: Towards an EU action plan, Genome Medicine 8.
- Wit, D. de; Schneider, T.C.; Moes, D.J.A.R.; Roozen, C.F.M.; Hartigh, J. den; Gelderblom, H.; Guchelaar, H.J.; Hoeven, J.J. van der; Links, T.P.; Kapiteijn, E. & Erp, N.P. van (2016), Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer, Cancer Chemotherapy and Pharmacology 78(1): 63-71.
- Lunenburg, C.A.T.C.; Staveren, M.C. van; Gelderblom, H.; Guchelaar, H.J. & Swen, J.J. (2016), Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients, Pharmacogenomics 17(7): 721-729.
- Staveren, M.C. van; Kuilenburg, A.B.P. van; Guchelaar, H.J.; Meijer, J.; Punt, C.J.A.; Jong, R.S. de; Gelderblom, H. & Maring, J.G. (2016), Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy, British Journal of Clinical Pharmacology 81(3): 553-561.
- Diekstra, M.H.M.; Swen, J.J.; Gelderblom, H. & Guchelaar, H.J. (2016), A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review, Expert Review of Molecular Diagnostics 16(5): 605-618.
- Moes, D.J.A.R.; Bent, S.A.S. van der; Swen, J.J.; Straaten, T. van der; Inderson, A.; Olofsen, E.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2016), Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients, European Journal of Clinical Pharmacology 72(2): 163-174.
- Wilde, S. de; Guchelaar, H.J.; Zandvliet, M.L. & Meij, P. (2016), Clinical development of gene- and cell-based therapies: overview of the European landscape, Molecular Therapy - Methods and Clinical Development 3.
- Wouden, C.H. van der; Swen, J.J.; Samwald, M.; Mitropoulou, C.; Schwab, M.; Guchelaar, H.J. & Ubiquitous-Pharmacogenomics (2016), A brighter future for the implementation of pharmacogenomic testing, European Journal of Human Genetics 24(12): 1658-1660.
- Moes, D.J.A.R.; Swen, J.J.; Bent, S.A.S. van der; Straaten, T. van der; Inderson, A.; Olofsen, E.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2016), Response: Limited sampling strategies for once daily tacrolimus exposure monitoring, European Journal of Clinical Pharmacology 72(6): 775-776.
- Wilde, S. de; Guchelaar, H.J.; Herberts, C.; Lowdell, M.; Hildebrandt, M.; Zandvliet, M. & Meij, P. (2016), Development of cell therapy medicinal products by academic institutes, Drug Discovery Today 21(8): 1206-1212.
- Vos, H.I.; Coenen, M.J.H.; Guchelaar, H.J. & Loo, D.M.W.M. te (2016), The role of pharmacogenetics in the treatment of osteosarcoma, Drug Discovery Today 21(11): 1775-1786.
- Lam, S.W.; Guchelaar, H.J. & , E. boven (2016), The role of pharmacogenetics in capecitabine efficacy and toxicity, Cancer Treatment Reviews 50: 9-22.
- Mirzakhani, H.; Guchelaar, H.J.; Welch, C.A.; Cusin, C.; Doran, M.E.; MacDonald, T.O.; Bittner, E.A.; Eikermann, M. & Nozari, A. (2016), Minimum Effective Doses of Succinylcholine and Rocuronium During Electroconvulsive Therapy: A Prospective, Randomized, Crossover Trial, Anesthesia and Analgesia 123(3): 587-596.
- Beusekom, M.M. van; Grootens-Wiegers, P.; Bos, M.J.W.; Guchelaar, H.J. & Broek, J.M. van den (2016), Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images, International Journal of Clinical Pharmacy 38(6): 1372-1379.
- Lam, S.W.; Frederiks, C.N.; Straaten, T. van der; Honkoop, A.H.; Guchelaar, H.J. & , E. boven (2016), Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients, British Journal of Cancer 115(11): 1335-1342.
- Moes, D.J.A.R.; Press, R.R.; Ackaert, O.; Ploeger, B.A.; Bemelman, F.J.; Diack, C.; Wessels, J.A.M.; Straaten, T. van der; Danhof, M.; Sanders, J.S.F.; Heide, J.J.H. van der; Guchelaar, H.J. & Fijter, J.W. de (2016), Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients, British Journal of Clinical Pharmacology 82(1): 227-237.
- Wilde, S. de; Veltrop-Duits, L.; Hoozemans-Strik, M.; Ras, T.; Blom-Veenman, J.; Guchelaar, H.J.; Zandvliet, M. & Meij, P. (2016), Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation, Cytotherapy 18(6): 797-805.
- Groot, S. de; Charehbili, A.; Laarhoven, H.W.M. van; Mooyaart, A.L.; Dekker-Ensink, N.G.; Ven, S. van de; Janssen, L.G.M.; Swen, J.J.; Smit, V.T.H.B.M.; Heijns, J.B.; Kessels, L.W.; Straaten, T. van der; Bohringer, S.; Gelderblom, H.; Hoeven, J.J.M. van der; Guchelaar, H.J.; Pijl, H.; Kroep, J.R. & Dutch Breast Canc Res Grp (2016), Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01), Breast Cancer Research 18.
- Lunenburg, C.A.T.C.; Henricks, L.M.; Guchelaar, H.J.; Swen, J.J.; Deenen, M.J.; Schellens, J.H.M. & Gelderblom, H. (2016), Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time, European Journal of Cancer 54: 40-48.
- Moes, D.J.A.R.; Press, R.R.; Ackaert, O.; Ploeger, B.A.; Bemelman, F.J.; Diack, C.; Wessels, J.A.M.; Straaten, T. van der; Danhof, M.; Sanders, J.S.F.; Heide, J.J.H. van der; Guchelaar, H.J. & Fijter, J.W. de (2016), Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients, British Journal of Clinical Pharmacology 82(1): 227-237.
- Rongen, A. van; Kervezee, L.; , J.E.B. m; Meir, H. van; Hartigh, J. den; Guchelaar, H.J.; Meijer, J.H.; Burggraaf, J. & Oosterhout, F. van (2015), Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers, CPT: Pharmacometrics and Systems Pharmacology 4(8): 454-464.
- Huis-Tanja, L.H. van; Ewing, E.; Straaten, R.J.H.M. van der; Swen, J.J.; Baak-Pablo, R.F.; Punt, C.J.A.; Gelderblom, A.J. & Guchelaar, H.J. (2015), Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients, Pharmacogenetics and Genomics 25(6): 279-288.
- Silva, A.L.; Rosalia, R.A.; Varypataki, E.; Sibuea, S.; Ossendorp, F. & Jiskoot, W. (2015), Poly-(lactic-co-glycolic-acid)-based particulate vaccines: Particle uptake by dendritic cells is a key parameter for immune activation, Vaccine 33(7): 847-854.
- Bank, P.C.D.; Swen, J.J.; Guchelaar, H.J. & Straaten, T. van der (2015), GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population, Pharmacogenomics 16(7): 681-687.
- Vos, H.I.; Straaten, T. van der; Coenen, M.J.H.; Flucke, U.; Loo, D.M.W.M. te & Guchelaar, H.J. (2015), High-Quality Genotyping Data from Formalin-Fixed, Paraffin-Embedded Tissue on the Drug Metabolizing Enzymes and Transporters Plus Array, Journal of Molecular Diagnostics 17(1): 4-9.
- Coenen, M.J.H.; Jong, D.J. de; Marrewijk, C.J. van; Derijks, L.J.J.; Vermeulen, S.H.; Wong, D.R.; Klungel, O.H.; Verbeek, A.L.M.; Hooymans, P.M.; Peters, W.H.M.; Morsche, R.H.M. te; Newman, W.G.; Scheffer, H.; Guchelaar, H.J. & Franke, B. (2015), Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
- Wit, D. de; Guchelaar, H.J.; Hartigh, J. den; Gelderblom, H. & Erp, N.P. van (2015), Individualized dosing of tyrosine kinase inhibitors: are we there yet?, Drug Discovery Today 20(1): 18-36.
- Staveren, M.C. van; Opdam, F.; Guchelaar, H.J.; Kuilenburg, A.B.P. van; Maring, J.G. & Gelderblom, H. (2015), Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients, Cancer Chemotherapy and Pharmacology 76(1): 47-52.
- Beusekom, M. van; Bos, M.; Wolterbeek, R.; Guchelaar, H.J. & Broekb, J. van den (2015), Patients' preferences for visuals: Differences in the preferred level of detail, type of background and type of frame of icons depicting organs between literate and low-literate people, Patient Education and Counseling 98(2): 226-233.
- Pander, J.; Huis-Tanja, L. van; Bohringer, S.; Straaten, T. van der; Gelderblom, H.; Punt, C. & Guchelaar, H.J. (2015), Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer, PLoS ONE 10(7).
- Frederiks, C.N.; Lam, S.W.; Guchelaar, H.J. & , E. boven (2015), Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review, Cancer Treatment Reviews 41(10): 935-950.
- Lam, S.W.; Frederiks, C.N.; Straaten, T. van der; Groot, S.M. de; Jager, A.; Bos, M.M.E.M.; Linn, S.C.; Bosch, J. van den; Braun, H.J.; Velden, A.M.T. van der; , M. los; Portielje, J.E.A.; Kroep, J.R.; Honkoop, A.H.; Smorenburg, C.H.; Tanis, B.; Riel, J.M.G.H. van; Terwogt, J.M.M.; Boer, M.O. den; Douma, J.; Jeurissen, F.; Berends, J.; Guchelaar, H.J. & , E. boven (2015), Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients, Cancer Research 75(9).
- Mirzakhani, H.; Noorden, M.S. van; Swen, J.; Nozari, A. & Guchelaar, H.J. (2015), Pharmacogenetics in electroconvulsive therapy and adjunctive medications, Pharmacogenomics 16(9): 1015-1031.
- Opdam, F.L.; Modak, A.S.; Gelderblom, H. & Guchelaar, H.J. (2015), Further characterization of a C-13-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy, Journal of Breath Research 9(2).
- Davila-Fajardo, C.L.; Straaten, T. van der; Baak-Pablo, R.; Caballero, C.M.; Barrera, J.C.; Huizinga, T.W.; Guchelaar, H.J. & Swen, J.J. (2015), FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis, Pharmacogenomics 16(4): 373-381.
- Charehbili, A.; Groot, S. de; Straaten, T. van der; Swen, J.J.; Pijl, H.; Gelderblom, H.; Velde, C.J.H. van de; Nortier, J.W.R.; Guchelaar, H.J. & Kroep, J.R. (2015), Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia, Pharmacogenomics 16(11): 1265-1274.
- Mirkov, M.U.; Janss, L.; Vermeulen, S.H.; Laar, M.A.F.J. van de; Riel, P.L.C.M. van; Guchelaar, H.J.; Brunner, H.G.; Albers, C.A. & Coenen, M.J.H. (2015), Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases 74(12): 2183-2187.
- Wit, D. de; Hartigh, J. den; Gelderblom, H.; Qian, Y.W.; Hollander, M. den; Verheul, H.; Guchelaar, H.J. & Erp, N.P. van (2015), Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Pazopanib, Journal of Clinical Pharmacology 55(12): 1344-1350.
- Baas, J.M.; Krens, L.L.; Tije, A.J. ten; Erdkamp, F.; Wezel, T. van; Morreau, H.; Gelderblom, H. & Guchelaar, H.J. (2015), Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients.
- Baas, J.M.; Krens, L.L.; Bos, M.M.; Portielje, J.E.A.; Batman, E.; Wezel, T. van; Morreau, H.; Guchelaar, H.J. & Gelderblom, H. (2015), Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients, Anti-Cancer Drugs 26(8): 872-877.
- Kerkhofs, T.M.A.; Derijks, L.J.J.; Ettaieb, H.; Hartigh, J. den; Neef, K.; Gelderblom, H.; Guchelaar, H.J. & Haak, H.R. (2015), Development of a Pharmacokinetic Model of Mitotane: Toward Personalized Dosing in Adrenocortical Carcinoma, Therapeutic Drug Monitoring 37(1): 58-65.
- Moes, D.J.A.R.; Guchelaar, H.J. & Fijter, J.W. de (2015), Sirolimus and everolimus in kidney transplantation, Drug Discovery Today 20(10): 1243-1249.
- Welzen, M.E.B.; Dezentje, V.O.; Schaik, R.H.N. van; Colbers, A.P.H.; Guchelaar, H.J.; Erp, N.P. van; Hartigh, J. den; Burger, D.M. & Laarhoven, H.W.M. van (2015), The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity, Therapeutic Drug Monitoring 37(4): 501-507.
- Wit, D. de; Erp, N.P. van; Hartigh, J. den; Wolterbeek, R.; Hollander-van Deursen, M. den; Labots, M.; Guchelaar, H.J.; Verheul, H.M. & Gelderblom, H. (2015), Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib: A Pharmacokinetic Feasibility Study, Therapeutic Drug Monitoring 37(3): 331-338.
- Henricks, L.M.; Lunenburg, C.A.T.C.; Meulendijks, D.; Gelderblom, H.; Cats, A.; Swen, J.J.; Schellens, J.H.M. & Guchelaar, H.J. (2015), Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score, Pharmacogenomics 16(11): 1275-1284.
- Liu, X.; Diekstra, M.H.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B.I. & Guchelaar, H. (2015), Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma, European Journal of Clinical Pharmacology 71(12): 1477-1484.
- Schneider, T.C.; Wit, D. de; Links, T.P.; Erp, N.P. van; Hoeven, J.J.M. van der; Gelderblom, H.; Wezel, T. van; Eijk, R. van; Morreau, H.; Guchelaar, H.J. & Kapiteijn, E. (2015), Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial, International Journal of Endocrinology.
- Dezentje, V.O.; Opdam, F.L.; Gelderblom, H.; Hartigh, J. den; Straaten, T. van der; Vree, R.; Maartense, E.; Smorenburg, C.H.; Putter, H.; Dieudonne, A.S.; Neven, P.; Velde, C.J.H. van de; Nortier, J.W.R. & Guchelaar, H.J. (2015), CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects, Breast Cancer Research and Treatment 153(3): 583-590.
- Opdam, F.L.; Modak, A.S.; Mooijaart, S.P.; Louwerens, M.; Waal, M.W.M. de; Gelderblom, H. & Guchelaar, H.J. (2015), CYP2D6 Metabolism in Frail Elderly Compared to Non-Frail Elderly: A Pilot Feasibility Study, Drugs and Aging 32(12): 1019-1027.
- Diekstra, M.H.M.; Swen, J.J.; , E. boven; Castellano, D.; Gelderblom, H.; Mathijssen, R.H.J.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B.I. & Guchelaar, H.J. (2015), CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma, European Urology 68(4): 621-629.
- Mirzakhani, H.; Dormolen, J. van; Weide, K. van der; Guchelaar, H.J.; Noorden, M.S. van & Swen, J. (2015), Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy, Pharmacogenetics and Genomics 25(10): 515-517.
- Hagleitner, M.M.; Coenen, M.J.H.; Gelderblom, H.; Makkinje, R.R.; Vos, H.I.; Bont, E.S.J.M. de; Graaf, W.T.A. van der; Schreuder, H.W.B.; Flucke, U.; Leeuwen, F.N. van; Hoogerbrugge, P.M.; Guchelaar, H.J. & Loo, D.M.W.M. te (2015), A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment, Clinical Cancer Research 21(15): 3436-3441.
- Diekstra, M.; Swen, J.J.; , E. boven; Castellano, D.; Ganapathi, R.; Gelderblom, H.; Mathijssen, R.H.; Rodriguez-Antona, C.; Garcia-Donas, J.; Rini, B. & Guchelaar, H. (2015), A MULTICENTER VALIDATION STUDY OF GENETIC POLYMORPHISMS ASSOCIATED WITH TOXICITY AND EFFICACY OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA., Clinical Pharmacology and Therapeutics 97: S58-S58.
- Dezentje, V.O.; Gelderblom, H.; Schaik, R.H.N. van; Vletter-Bogaartz, J.M.; Straaten, T. van der; Wessels, J.A.M.; Kranenbarg, E.M.K.; Berns, E.M.; Seynaeve, C.; Putter, H.; Velde, C.J.H. van de; Nortier, J.W.R. & Guchelaar, H.J. (2014), CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial, Breast Cancer Research and Treatment 143(1): 171-179.
- Wit, D. de; Erp, N.P. van; Khosravan, R.; Wiltshire, R.; Allred, R.; Demetri, G.D.; Guchelaar, H.J. & Gelderblom, H. (2014), Effect of gastrointestinal resection on sunitinib exposure in patients with GIST, BMC Cancer 14.
- Huis-Tanja, L.H. van; Kweekel, D.M.; Lu, X.B.; Franken, K.; Koopman, M.; Gelderblom, H.; Antonini, N.F.; Punt, C.J.A.; Guchelaar, H.J. & Straaten, T. van der (2014), Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin, Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis 759: 37-44.
- Bank, P.C.D.; Guchelaar, H.J. & Swen, J.J. (2014), Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule, Internal and Emergency Medicine 9(4): 481-482.
- Okada, Y.; Wu, D.; Trynka, G.; Raj, T.; Terao, C.; Ikari, K.; Kochi, Y.; Ohmura, K.; Suzuki, A.; Yoshida, S.; Graham, R.R.; Manoharan, A.; Ortmann, W.; Bhangale, T.; Denny, J.C.; Carroll, R.J.; Eyler, A.E.; Greenberg, J.D.; Kremer, J.M.; Pappas, D.A.; Jiang, L.; Yin, J.; Ye, L.Y.; Su, D.F.; Yang, J.; Xie, G.; Keystone, E.; Westra, H.J.; Esko, T.; Metspalu, A.; Zhou, X.Z.; Gupta, N.; Mirel, D.; Stahl, E.A.; Diogo, D.; Cui, J.; Liao, K.; Guo, M.H.; Myouzen, K.; Kawaguchi, T.; Coenen, M.J.H.; Riel, P.L.C.M. van; Laar, M.A.F.J. van de; Guchelaar, H.J.; Huizinga, T.W.J.; Dieude, P.; Mariette, X.; Bridges, S.L.; Zhernakova, A.; Toes, R.E.M.; Tak, P.P.; Miceli-Richard, C.; Bang, S.Y.; Lee, H.S.; Martin, J.; Gonzalez-Gay, M.A.; Rodriguez-Rodriguez, L.; Rantapaa-Dahlqvist, S.; Arlestig, L.; Choi, H.K.; Kamatani, Y.; Galan, P.; Lathrop, M.; Eyre, S.; Bowes, J.; Barton, A.; Vries, N. de; Moreland, L.W.; Criswell, L.A.; Karlson, E.W.; Taniguchi, A.; Yamada, R.; Kubo, M.; Liu, J.S.; Bae, S.C.; Worthington, J.; Padyukov, L.; Klareskog, L.; Gregersen, P.K.; Raychaudhuri, S.; Stranger, B.E.; Jager, P.L. de; Franke, L.; Visscher, P.M.; Brown, M.A.; Yamanaka, H.; Mimori, T.; Takahashi, A.; Xu, H.J.; Behrens, T.W.; Siminovitch, K.A.; Momohara, S.; Matsuda, F.; Yamamoto, K.; Plenge, R.M.; RACI Consortium & GARNET Consortium (2014), Genetics of rheumatoid arthritis contributes to biology and drug discovery, Nature 506(7488): 376-+.
- Fontein, D.B.Y.; Houtsma, D.; Nortier, J.W.R.; Baak-Pablo, R.F.; Kranenbarg, E.M.K.; Straaten, T.R.J.H.M. van der; Putter, H.; Seynaeve, C.; Gelderblom, H.; Velde, C.J.H. van de & Guchelaar, H.J. (2014), Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial, Breast Cancer Research and Treatment 144(3): 599-606.
- Slingerland, M.; Guchelaar, H.J. & Gelderblom, H. (2014), Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors, Anti-Cancer Drugs 25(2): 140-149.
- Wong, D.; Coenen, M.; Derijks, L.; Marrewijk, C. van; Vermeulen, S.; Verbeek, A.; Franke, B.; Guchelaar, H.J.; Jong, D. de; Engels, L. & Hooymans, P. (2014), Early assessment of thiopurine metabolites predicts the occurrence of leukopenia in inflammatory bowel disease patients, Journal of Crohn's and Colitis 8: S31-S32.
- Staveren, M.C. van; Kuilenburg, A.B.P. van; Guchelaar, H.J.; Jong, R. de; Punt, C.J.A.; Gelderblom, H. & Maring, J.G. (2014), Sensitivity and specificity of an oral uracil-loading test dose for screening for DPD deficiency, Journal of Clinical Oncology 32(15).
- Hagleitner, M.M.; Coenen, M.J.H.; Patino-Garcia, A.; Bont, E.S.J.M. de; Gonzalez-Neira, A.; Vos, H.I.; Leeuwen, F.N. van; Gelderblom, H.; Hoogerbrugge, P.M.; Guchelaar, H.J. & Loo, M.W.M. te (2014), Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts, PLoS ONE 9(12).
- Okada, Y.; Diogo, D.; Greenberg, J.D.; Mouassess, F.; Achkar, W.A.L.; Fulton, R.S.; Denny, J.C.; Gupta, N.; Mirel, D.; Gabriel, S.; Li, G.; Kremer, J.M.; Pappas, D.A.; Carroll, R.J.; Eyler, A.E.; Trynka, G.; Stahl, E.A.; Cui, J.; Saxena, R.; Coenen, M.J.H.; Guchelaar, H.J.; Huizinga, T.W.J.; Dieude, P.; Mariette, X.; Barton, A.; Canhao, H.; Fonseca, J.E.; Vries, N. de; Tak, P.P.; Moreland, L.W.; Bridges, S.L.; Miceli-Richard, C.; Choi, H.K.; Kamatani, Y.; Galan, P.; Lathrop, M.; Raj, T.; Jager, P.L. de; Raychaudhuri, S.; Worthington, J.; Padyukov, L.; Klareskog, L.; Siminovitch, K.A.; Gregersen, P.K.; Mardis, E.R.; Arayssi, T.; Kazkaz, L.A. & Plenge, R.M. (2014), Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene, PLoS ONE 9(2).
- Wit, D. de; Gelderblom, H.; Sparreboom, A.; Hartigh, J. den; Hollander, M. den; Konig-Quartel, J.M.C.; Hessing, T.; Guchelaar, H.J. & Erp, N.P. van (2014), Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer, Cancer Chemotherapy and Pharmacology 73(1): 87-96.
- Brink, M.H. ten; Zwaveling, J.; Swen, J.J.; Bredius, R.G.M.; Lankester, A.C. & Guchelaar, H.J. (2014), Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics, Drug Discovery Today 19(10): 1572-1586.
- Bank, P.C.; Swen, J.J. & Guchelaar, H.J. (2014), Pharmacogenetic biomarkers for predicting drug response, Expert Review of Molecular Diagnostics 14(6): 723-735.
- Guchelaar, H.J.; Gelderblom, H.; Straaten, T.D.; Schellens, J.H.M. & Swen, J.J. (2014), Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation Sequencing.
- Nagtegaal, M.J.; Swen, J.J.; Hanff, L.M.; Schimmel, K.J.M. & Guchelaar, H.J. (2014), Pharmacogenetics of taste: turning bitter pills sweet?, Pharmacogenomics 15(1): 111-119.
- Krens, L.L.; Baas, J.M.; Verboom, M.C.; Paintaud, G.; Desvignes, C.; Guchelaar, H.J. & Gelderblom, H. (2014), Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction, Cancer Chemotherapy and Pharmacology 73(6): 1303-1306.
- Krens, L.L.; Baas, J.M.; Jong, F.A. de; Guchelaar, H.J. & Gelderblom, H. (2014), Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report, Cancer Chemotherapy and Pharmacology 73(2): 429-433.
- Brink, M. ten; Ackaert, O.; Zwaveling, J.; Bredius, R.G.; Smiers, F.J.; Hartigh, J. den; Lankester, A.C. & Guchelaar, H. (2014), Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation, Therapeutic Drug Monitoring 36(4): 465-472.
- Moes, D.J.A.R.; Bent, S.A.S. van der; Swen, J.J.; Straaten, T.; Verspaget, H.W.; Guchelaar, H.J.; Hartigh, J. den & Hoek, B. van (2014), Population Pharmacokinetics and Pharmacogenetics of Once Daily Tacrolimus Formulation in Liver Transplant Patients., Liver Transplantation 20: S106-S107.
- Krens, L.L.; Pullen, C.M.C.; Baak-Pablo, R.F.; Guchelaar, H.J. & Straaten, R.J.H.M. van der (2014), SIMVASTATIN CAUSES TRANSLOCATION OF MUTANT K-RAS IN COLORECTAL CANCER CELLS, British Journal of Clinical Pharmacology 78(4): 768-769.
- Krens, L.L.; Simkens, L.H.J.; Baas, J.M.; Koomen, E.R.; Gelderblom, H.; Punt, C.J.A. & Guchelaar, H.J. (2014), Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study, PLoS ONE 9(11).
- Brink, M. ten; Bavel, T. van; Swen, J.J.; Straaten, T. van der; Bredius, R.G.; Lankester, A.C.; Zwaveling, J. & Guchelaar, H. (2014), THE ROLE OF GENETIC VARIANTS GSTA1 AND CYP39A1 AND ONTOGENESIS ON BUSULFAN CLEARANCE IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC SCT., Clinical Pharmacology and Therapeutics 95: S100-S100.
- Kerkhofs, T.M.A.; Derijks, L.J.J.; Ettaieb, M.H.T.; Eekhoff, E.M.W.; Neef, C.; Gelderblom, H.; Hartigh, J. den; Guchelaar, H.J. & Haak, H.R. (2014), Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring, European Journal of Endocrinology 171(6): 677-683.
- Brink, M. ten; Bredius, R.; Zwaveling, J.; Smiers, F.; Hartigh, J. den; Guchelaar, H.J.; Lankester, A. & Pediat Dis Inborn Errors (2014), THE PHARMACOKINETIC PROFILE OF TREOSULFAN IN PEDIATRIC PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Bone Marrow Transplantation 49: S364-S365.
- Brink, M.H. ten; Bredius, R.G.M.; Zwaveling, J.; Ackaert, O.; Hartigh, J. den; Smiers, F.J.; Guchelaar, H.J. & Lankester, A. (2014), Treosulfan-Based Conditioning in Pediatric Hematopoietic Stem Cell Transplantation: A Prospective Study on Pharmacokinetics and Early Clinical Outcomes, Blood 124(21).
- Houtsma, D.; Groot, S. de; Straaten, T. van der; Baak-Pablo, R.; Velde, C.J.H. van der; Guchelaar, H.J. & Gelderblom, H. (2014), Variation in the ESR-1 gene as a prognostic marker in early breast cancer survival, Journal of Clinical Oncology 32(15).
- Gelderblom, H.; Blay, J.Y.; Seddon, B.M.; Leahy, M.; Ray-Coquard, I.; Sleijfer, S.; Kerst, J.M.; Rutkowski, P.; Bauer, S.; Ouali, M.; Marreaud, S.; Straaten, R.J.H.M. van der; Guchelaar, H.J.; Weitman, S.D.; Hogendoorn, P.C.W. & Hohenberger, P. (2014), Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study, European Journal of Cancer 50(2): 388-396.
- Vos, H.I.; Coenen, M.J.H.; Gelderblom, H.; Straaten, T. van der; Bont, E.S.J.M. de; Graaf, W.T.A. van der; Schreuder, H.W.B.; Leeuwen, F.N. van; Guchelaar, H.J. & Loo, D.M.W.M.T. (2014), Association of genetic variants involved in drug metabolism and transport with efficacy and toxicity of chemotherapeutic treatment in osteosarcoma patients., Journal of Clinical Oncology 32(15).
- Straaten, T. van der; Martijn, R.; Hajoui, T. el; Baak-Pablo, R. & Guchelaar, H.J. (2013), A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B, Pharmacogenetics and Genomics 23(11): 631-635.
- Rommers, M.K.; Zwaveling, J.; Guchelaar, H.J. & Teepe-Twiss, I.M. (2013), Evaluation of rule effectiveness and positive predictive value of clinical rules in a Dutch clinical decision support system in daily hospital pharmacy practice, Artificial Intelligence in Medicine 59(1): 15-21.
- Verschuren, J.J.W.; Boden, H.; Wessels, J.A.M.; Hoeven, B.L. van der; Trompet, S.; Heijmans, B.T.; Putter, H.; Guchelaar, H.J.; Schalij, M.J. & Jukema, J.W. (2013), Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction, International Journal of Cardiology 167(6): 2882-2888.
- Staveren, M.C. van; Guchelaar, H.J.; Kuilenburg, A.B.P. van; Gelderblom, H. & Maring, J.G. (2013), Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency, Pharmacogenomics Journal 13(5): 389-395.
- Moes, D.J.A.R.; Swen, J.J.; Hartigh, J. den; Straaten, T. van der; Heide, J.J.H. van der; Bemelman, F.; Fijter, J.W. de & Guchelaar, H.J. (2013), Evaluating the Effect of CYP3A4 and CYP3A5 Polymorphisms on Cyclosporine, Everolimus and Tacrolimus Pharmacokinetics in Renal Transplantation Patients, Therapeutic Drug Monitoring 35(5): 672-672.
- Brink, M.H. ten; Bavel, T. van; Swen, J.J.; Straaten, T. van der; Bredius, R.G.M.; Lankester, A.C.; Zwaveling, J. & Guchelaar, H.J. (2013), Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation, Pharmacogenomics 14(14): 1683-1690.
- Opdam, F.L.; Dezentje, V.O.; Hartigh, J. den; Modak, A.S.; Vree, R.; Batman, E.; Smorenburg, C.H.; Nortier, J.W.R.; Gelderblom, H. & Guchelaar, H.J. (2013), The use of the C-13-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels, Cancer Chemotherapy and Pharmacology 71(3): 593-601.
- Dezentje, V.O.; Schaik, R.H.N. van; Vletter-Bogaartz, J.M.; Straaten, T. van der; Wessels, J.A.M.; Kranenbarg, E.M.K.; Berns, E.M.; Seynaeve, C.; Putter, H.; Velde, C.J.H. van de; Nortier, J.W.R.; Gelderblom, H. & Guchelaar, H.J. (2013), CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial, Breast Cancer Research and Treatment 140(2): 363-373.
- Plenge, R.M.; Greenberg, J.D.; Mangravite, L.M.; Derry, J.M.J.; Stahl, E.A.; Coenen, M.J.H.; Barton, A.; Padyukov, L.; Klareskog, L.; Gregersen, P.K.; Mariette, X.; Moreland, L.W.; Bridges, S.L.; Vries, N. de; Huizinga, T.W.J.; Guchelaar, H.J.; Friend, S.H.; Stolovitzky, G. & Int Rheumatoid Arthritis (2013), Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge, Nature Genetics 45(5): 468-469.
- Huis-Tanja, L. van; Kweekel, D.; Gelderblom, H.; Koopman, M.; Punt, K.; Guchelaar, H.J. & Straaten, T. van der (2013), Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples, Pharmacogenomics 14(16): 2005-2012.
- Leeuwen, N. van; Swen, J.J.; Guchelaar, H.J. & 'tHart, L.M. (2013), The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs, Clinical Pharmacokinetics 52(10): 833-854.
- Mirkov, M.U.; Cui, J.; Vermeulen, S.H.; Stahl, E.A.; Toonen, E.J.M.; Makkinje, R.R.; Lee, A.T.; Huizinga, T.W.J.; Allaart, R.; Barton, A.; Mariette, X.; Miceli, C.R.; Criswell, L.A.; Tak, P.P.; Vries, N. de; Saevarsdottir, S.; Padyukov, L.; Bridges, S.L.; Schaardenburg, D.J. van; Jansen, T.L.; Dutmer, E.A.J.; Laar, M.A.F.J.V. de; Barrera, P.; Radstake, T.R.D.J.; Riel, P.L.C.M. van; Scheffer, H.; Franke, B.; Brunner, H.G.; Plenge, R.M.; Gregersen, P.K.; Guchelaar, H.J. & Coenen, M.J.H. (2013), Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases 72(8): 1375-1381.
- Davila-Fajardo, C.L.; Swen, J.J.; Straaten, T. van der & Guchelaar, H.J. (2013), Centres of Excellence Course in Pharmacogenetics, 25-28 June 2012, European Journal of Hospital Pharmacy 20(2): 132-132.
- Slingerland, M.; Cerella, C.; Guchelaar, H.J.; Diederich, M. & Gelderblom, H. (2013), Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials.
- Opdam, F.L.; Modak, A.S.; Gelderblom, H. & Guchelaar, H.J. (2013), Breath Tests to Phenotype Drug Disposition in Oncology, Clinical Pharmacokinetics 52(11): 919-926.
- Cui, J.; Stahl, E.A.; Saevarsdottir, S.; Miceli, C.; Diogo, D.; Trynka, G.; Raj, T.; Mirkov, M.U.; Canhao, H.; Ikari, K.; Terao, C.; Okada, Y.; Wedren, S.; Askling, J.; Yamanaka, H.; Momohara, S.; Taniguchi, A.; Ohmura, K.; Matsuda, F.; Mimori, T.; Gupta, N.; Kuchroo, M.; Morgan, A.W.; Isaacs, J.D.; Wilson, A.G.; Hyrich, K.L.; Herenius, M.; Doorenspleet, M.E.; Tak, P.P.; Crusius, J.B.A.; Horst-Bruinsma, I.E. van der; Wolbink, G.J.; Riel, P.L.C.M. van; Laar, M. van de; Guchelaar, H.J.; Shadick, N.A.; Allaart, C.F.; Huizinga, T.W.J.; Toes, R.E.M.; Kimberly, R.P.; Bridges, S.L.; Criswell, L.A.; Moreland, L.W.; Fonseca, J.E.; Vries, N. de; Stranger, B.E.; Jager, P.L. de; Raychaudhuri, S.; Weinblatt, M.E.; Gregersen, P.K.; Mariette, X.; Barton, A.; Padyukov, L.; Coenen, M.J.H.; Karlson, E.W. & Plenge, R.M. (2013), Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis, PLoS Genetics 9(3).
- Huis-Tanja, L.H. van; Gelderblom, H.; Punt, C.J.A. & Guchelaar, H.J. (2013), MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer, Pharmacogenetics and Genomics 23(4): 208-218.
- Slingerland, M.; Guchelaar, H.J.; Rosing, H.; Scheulen, M.E.; Warmerdam, L.J.C. van; Beijnen, J.H. & Gelderblom, H. (2013), Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer, Clinical Therapeutics 35(12): 1946-1954.
- Erp, N.P. van; Wit, D. de; Guchelaar, H.J.; Gelderblom, H.; Hessing, T.J. & Hartigh, J. den (2013), A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry, Journal of Chromatography B 937: 33-43.
- Verschuren, J.J.W.; Trompet, S.; Deelen, J.; Stott, D.J.; Sattar, N.; Buckley, B.M.; Ford, I.; Heijmans, B.T.; Guchelaar, H.J.; Houwing-Duistermaat, J.J.; Slagboom, P.E. & Jukema, J.W. (2013), Non-Homologous End-Joining Pathway Associated with Occurrence of Myocardial Infarction: Gene Set Analysis of Genome-Wide Association Study Data, PLoS ONE 8(2).
- Krens, L.; Pullen, C.M.C.; Baak-Pablo, R.F.; Guchelaar, H.J. & Straaten, R.J.H.M. van der (2013), Simvastatin induces KRAS translocation in KRAS mutant colorectal cancer cells and may influence the susceptibility to anti-EGFR therapy, European Journal of Cancer 49: S495-S495.
- Brink, M.H. ten; Straaten, T. van der; Bouwsma, H.; Baak-Pablo, R.; Guchelaar, H.J. & Swen, J.J. (2013), Pharmacogenetics in Transplant Patients: Mind the Mix, Clinical Pharmacology and Therapeutics 94(4): 443-444.
- Davila-Fajardo, C.L.; Swen, J.J.; Barrera, J.C. & Guchelaar, H.J. (2013), Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate, Pharmacogenomics 14(1): 63-73.
- Siiskonen, S.J.; Koomen, E.R.; Visser, L.E.; Herings, R.M.C.; Guchelaar, H.J.; Stricker, B.H.C. & Nijsten, T.E.C. (2013), Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma, European Journal of Clinical Pharmacology 69(7): 1437-1444.
- Brink, M.H. ten; Swen, J.J.; Bohringer, S.; Wessels, J.A.M.; Straaten, T. van der; Marijt, E.W.A.; Borne, P.A. von dem; Zwaveling, J. & Guchelaar, H.J. (2013), Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients, Pharmacogenetics and Genomics 23(12): 675-683.
- Dezentje, V.O.; Schalk, R.H.N. van; Vietter-Bogaartz, J.M.; Straaten, T. van der; Wessels, J.A.M.; Kranertharg, E.M.K.; Berns, E.M.J.J.; Seynaeve, C.; Putter, H.; Velde, C.J.H. van de; Nortier, J.W.R.; Gelderblom, H. & Guchelaar, H.J. (2013), CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential fake CYP2D6 genotype assignment caused by loss of hetcrozygosity in tumor tissue, Journal of Clinical Oncology 31(15).
- Erp, N.P. van; Wit, D. de; Sparreboom, A.; Hartigh, J. den; Hollander, M. den; Konig-Quartel, J.M.C.; Hessing, T.; Guchelaar, H.J. & Gelderblom, H. (2013), CYP3A4 phenotyping with midazolam to predict sunitinib exposure., Journal of Clinical Oncology 31(15).
- Opdam, F.; Dezentje, V.O.; Hartigh, J. den; Guchelaar, H.J.; Hessing, T.; Straaten, T. van der; Vree, R.; Batman, E.; Maartense, E.; Smorenburg, C.H.; Zeillemaker, A.; Brakenhoff, J.A.C.; , M. los; Kuijer, P.; Putter, H.; Dieudonne, A.S.; Maven, P.; Velde, C.J.H. van de; Nortier, J.W.R. & Gelderblom, H. (2013), Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers., Journal of Clinical Oncology 31(15).
- Brink, M.H. ten; Swen, J.J.; Zwaveling, J.; Straaten, T. van der; Wessels, J.A. & Guchelaar, H.J. (2013), EXPLORATORY ANALYSIS OF 1,936 SNPS IN 225 ADME GENES FOR ASSOCIATION WITH BUSULFAN CLEARANCE IN ADULT HEMATOPOIETIC STEM CELL RECIPIENTS, Clinical Pharmacology and Therapeutics 93: S5-S5.
- Brink, M.H. ten; Swen, J.J.; Zwaveling, J.; Straaten, T. van der; Wessels, J.A. & Guchelaar, H.J. (2013), EXPLORATORY ANALYSIS OF 1,936 SNPS IN 225 ADME GENES FOR ASSOCIATION WITH BUSULFAN CLEARANCE IN ADULT HEMATOPOIETIC STEM CELL RECIPIENTS, Clinical Pharmacology and Therapeutics 93: S87-S87.
- Houtsma, D.; Fontein, D.; Straaten, T. van der; Baak-Pablo, R.; Wessels, J.A.M.; Seynaeve, C.; Velde, C.J.H.V. de; Nortier, J.W.R.; Gelderblom, H. & Guchelaar, H.J. (2013), Genetic variation in CYP19A1 and occurrence of adverse events in exemestane treatment with early breast cancer patients in the Dutch TEAM trial., Journal of Clinical Oncology 31(15).
- Krens, L.; Baas, J.; Jong, F.A. de; Guchelaar, H.J. & Gelderblom, H. (2013), Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction, Journal of Clinical Oncology 31(4).
- Baas, J.M.; Krens, L.; Tije, A.J. ten; Erdkamp, F.; Guchelaar, H.J. & Gelderblom, H. (2013), Safety and efficacy of the addition of simvastatin to cetuximab in KRAS mutant metastatic colorectal cancer patients., Journal of Clinical Oncology 31(15).
- Guchelaar, H.J.; Baas, J.M.; Krens, L.; Bos, M.M.E.M.; Portielje, J.E.A.; Batman, E. & Gelderblom, H. (2013), Safety and efficacy of the addition of simvastatin to panitumumab in KRAS mutant metastatic colorectal cancer patients., Journal of Clinical Oncology 31(15).
- Wit, D. de; Erp, N.P. van; Khosravan, R.; Wiltshire, R.; Allred, R.U.; Demetri, G.D.; Guchelaar, H.J. & Gelderblom, H. (2013), The influence of gastrointestinal resection on sunitinib exposure in GIST patients., Journal of Clinical Oncology 31(15).
- Perwitasari, D.A.; Straaten, R.J.H.M. van der; Mustofa, M.; Wessels, J.A.M.; Gelderblom, H. & Guchelaar, H.J. (2012), Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians, International Journal of Biological Markers 27(1): 34-38.
- Dezentje, V.O.; Guchelaar, H.J.; Schaik, R.H.N. van; Vletter-Bogaartz, J.M.; Straaten, T. van der; Wessels, J.A.M.; Kranenbarg, E.M.K.; Hille, E.T.M.; Berns, E.M.; Seynaeve, C.M.; Putter, H.; Velde, C.J.H. van de; Nortier, J.W.R. & Gelderblom, H. (2012), Common polymorphisms in the estrogen receptor-1 may determine risk of hot flashes in early breast cancer patients using tamoxifen, Journal of Clinical Oncology 30(15).
- Hagleitner, M.M.; Coenen, M.J.H.; Gelderblom, H.; Hoogerbrugge, P.; Guchelaar, H.J. & Loo, D.M.W.M. te (2012), Association of the genetic variants in the nucleotide excision repair genes XPA and XPC with cisplatin-induced hearing loss in patients with osteosarcoma, Journal of Clinical Oncology 30(15).
- Swen, J.J.; Straaten, T. van der; Wessels, J.A.M.; Bouvy, M.L.; Vlassak, E.E.W.; Assendelft, W.J.J. & Guchelaar, H.J. (2012), Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19, European Journal of Clinical Pharmacology 68(4): 363-370.
- Fontein, D.B.Y.; Houtsma, D.; Hille, E.T.M.; Seynaeve, C.; Putter, H.; Kranenbarg, E.M.K.; Guchelaar, H.J.; Gelderblom, H.; Dirix, L.Y.; Paridaens, R.; Bartlett, J.M.S.; Nortier, J.W.R.; Velde, C.J.H. van de & Dutch TEAM Steering Comm (2012), Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients, Annals of Oncology 23(12): 3091-3097.
- Houtsma, D.; Fontein, D.; Wessels, J.A.M.; Seynaeve, C.M.; Velde, C.J.H. van de; Nortier, J.W.R.; Guchelaar, H.J. & Gelderblom, H. (2012), Genetic variation in CYP19A1 and response to exemestane: Survival in early breast cancer in the Dutch TEAM trial, Journal of Clinical Oncology 30(15).
- Straaten, T. van der; Guchelaar, H.J. & Swen, J.J. (2012), The challenges of developing a 'medical-grade' genome, Pharmacogenomics 13(4): 369-372.
- Verschuren, J.J.W.; Boden, H.; Wessels, J.A.; Hoeven, B.L. van der; Guchelaar, H.J.; Schalij, M. & Jukema, J. (2012), NO ASSOCIATION OF PARAOXONASE-1 Q192R AND THROMBOTIC EVENTS DURING DUAL ANTI-PLATELET THERAPY IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION, Journal of the American College of Cardiology 59(13): E458-E458.
- Opdam, F.L.; Guchelaar, H.J.; Beijnen, J.H. & Schellens, J.H.M. (2012), Lapatinib for Advanced or Metastatic Breast Cancer.
- Swen, J.J. & Guchelaar, H.J. (2012), Just how feasible is pharmacogenetic testing in the primary healthcare setting?, Pharmacogenomics 13(5): 507-509.
- Brink, M.H. ten; Wessels, J.A.; Hartigh, J. den; Straaten, T. van der; Borne, P.A.V.D.; Guchelaar, H.J. & Zwaveling, J. (2012), Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT, Bone Marrow Transplantation 47(2): 190-195.
- Swen, J.J.; Baak-Pablo, R.F.; Guchelaar, H.J. & Straaten, T. van der (2012), Alternative methods to a TaqMan assay to detect a tri-allelic single nucleotide polymorphism rs757210 in the HNF1 beta gene, Clinical Chemistry and Laboratory Medicine 50(2): 279-284.
- Fransen, J.; Kooloos, W.M.; Huizinga, T.W.J.; Guchelaar, H.J.; Riel, P.L.C.M. van & Barrera, P. (2012), Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure, Pharmacogenomics 13(9): 1087-1094.
- Moes, D.J.A.R.; Press, R.R.; Hartigh, J. den; Straaten, T. van der; Fijter, J.W. de & Guchelaar, H.J. (2012), Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients, Clinical Pharmacokinetics 51(7): 467-480.
- Baas, J.M.; Krens, L.L.; Guchelaar, H.J.; Ouwerkerk, J.; Jong, F.A. de; Lavrijsen, A.P.M. & Gelderblom, H. (2012), Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review, Cancer Treatment Reviews 38(5): 505-514.
- Hagleitner, M.M.; Coenen, M.J.H.; Bont, E.S.J.M. de; Graaf, W.T.A. van der; Schreuder, B.H.W.; Gelderblom, H.A.J.; Hoogerbrugge, P.M.; Guchelaar, H.J. & Loo, M.D.M.W. te (2012), PREDICTING DISEASE FREE SURVIVAL USING PHARMACOGENETICS IN PATIENTS WITH OSTEOSARCOMA, Pediatric Blood and Cancer 59(6): 976-976.
- Eechoute, K.; Veldt, A.A.M. van der; Oosting, S.; Kappers, M.H.W.; Wessels, J.A.M.; Gelderblom, H.; Guchelaar, H.J.; Reyners, A.K.L.; Herpen, C.M.L. van; Haanen, J.B.; Mathijssen, R.H.J. & , E. boven (2012), Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension.
- Opdam, F.L.; Gelderblom, H. & Guchelaar, H.J. (2012), Phenotyping drug disposition in oncology, Cancer Treatment Reviews 38(6): 715-725.
- Slingerland, M.; Guchelaar, H.J. & Gelderblom, H. (2012), Liposomal drug formulations in cancer therapy: 15 years along the road, Drug Discovery Today 17(3-4): 160-166.
- Opdam, F.L.; Dezentje, V.O.; Hartigh, J. den; Guchelaar, H.J. & Gelderblom, H. (2012), Emphasizing the Value of Phenotyping in Patients Receiving Tamoxifen.
- Arbouw, M.E.L.; Movig, K.L.L.; Guchelaar, H.J.; Neef, C. & Egberts, T.C.G. (2012), Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study, European Journal of Clinical Pharmacology 68(1): 83-88.
- Verschuren, J.J.W.; Trompet, S.; Wessels, J.A.M.; Guchelaar, H.J.; Maat, M.P.M. de; Simoons, M.L. & Jukema, J.W. (2012), A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?, European Heart Journal 33(2): 165-U148.
- Zandvliet, M.L.; Kester, M.G.D.; Liempt, E. van; Ru, A.H. de; Veelen, P.A. van; Griffioen, M.; Guchelaar, H.J.; Falkenburg, J.H.F. & Meij, P. (2012), Efficiency and Mechanism of Antigen-specific CD8(+) T-cell Activation Using Synthetic Long Peptides, Journal of Immunotherapy 35(2): 142-153.
- Verschuren, J.J.W.; Wessels, J.A.M.; Trompet, S.; Stott, D.J.; Sattar, N.; Buckley, B.; Guchelaar, H.J. & Jukema, J.W. (2012), Variation in DNA repair genes and risk of cardiovascular events, Cardiovascular Research 93: S94-S94.
- Verschuren, J.J.W.; Wessels, J.A.; Trompet, S.; Stott, D.J.; Sattar, N.; Buckley, B.; Guchelaar, H.J. & Jukema, J. (2012), GENETIC VARIATION IN THE SMARCA2 GENE IS ASSOCIATED WITH CARDIOVASCULAR EVENTS, Journal of the American College of Cardiology 59(13): E1393-E1393.
- Verschuren, J.J.W.; Boden, H.; Wessels, J.A.M.; Hoeven, B.L. van der; Trompet, S.; Heijmans, B.T.; Putter, H.; Guchelaar, H.J.; Schalij, M.J. & Jukema, J.W. (2012), Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction, European Heart Journal 33: 516-516.
- Perwitasari, D.A.; Atthobari, J.; Mustofa, M.; Dwiprahasto, I.; Hakimi, M.; Gelderblom, H.; Putter, H.; Nortier, J.W.R.; Guchelaar, H.J. & Kaptein, A.A. (2012), Impact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life in Indonesian Patients With Gynecologic Cancer.
- Pander, J.; Wessels, J.A.M.; Gelderblom, H.; Straaten, T. van der; Punt, C.J.A. & Guchelaar, H.J. (2011), Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer, Annals of Oncology 22(5): 1147-1153.
- Perwitasari, D.A.; Atthobari, J.; Dwiprahasto, I.; Hakimi, M.; Gelderblom, H.; Putter, H.; Nortier, J.W.R.; Guchelaar, H.J. & Kaptein, A.A. (2011), Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia, Japanese Journal of Clinical Oncology 41(4): 519-529.
- Dervieux, T.; Wessels, J.A.M.; Kremer, J.M.; Padyukov, L.; Seddighzadeh, M.; Saevarsdottir, S.; Vollenhoven, R.F. van; Klareskog, L.; Huizinga, T.W. & Guchelaar, H.J. (2011), Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis., Pharmacogenetics and Genomics.
- Swen, J.J.; Wessels, J.A.; Assendelft, W.J. & Guchelaar, H.J. (2011), GENETIC RISK FACTORS FOR TYPE 2 DIABETES MELLITUS AND RESPONSE TO SULFONYLUREA TREATMENT., Clinical Pharmacology and Therapeutics 89: S76S76.
- Steeghs, N.; Gelderblom, H.; Wessels, J.; Eskens, F.A.L.M.; Bont, N. de; Nortier, J.W.R. & Guchelaar, H.J. (2011), Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors., Investigational New Drugs.
- Swen, J.J. & Guchelaar, H.J. (2011), Pharmacogenetic dose recommendations in clinical practice, EJHP Practice 17(5): 28-29.
- Pander, J.; Heusinkveld, M.; Straaten, T. van der; Jordanova, E.S.; Baak-Pablo, R.; Gelderblom, H.; Morreau, H.; Burg, S.H. van der; Guchelaar, H.J. & Hall, T. van (2011), Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab, Clinical Cancer Research 17(17): 5668-5673.
- Zandvliet, M.L.; Liempt, E. van; Jedema, I.; Kruithof, S.; Kester, M.G.D.; Guchelaar, H.J.; Falkenburg, J.H.F. & Meij, P. (2011), Simultaneous Isolation of CD8(+) and CD4(+) T Cells Specific for Multiple Viruses for Broad Antiviral Immune Reconstitution After Allogeneic Stem Cell Transplantation, Journal of Immunotherapy 34(3): 307-319.
- Perwitasari, D.A.; Atthobari, J.; Mustofa, M.; Dwiprahasto, I.; Hakimi, M.; Gelderblom, H.; Putter, H.; Nortier, J.W.R.; Guchelaar, H.J. & Kaptein, A.A. (2011), Impact of Delayed Chemotherapy Induced Nausea and Vomiting on Quality of Life in Indonesian Patients with Gynecological Cancer, Pharmacoepidemiology and Drug Safety 20: S278S278.
- Opdam, F.L.; Ballieux, B.E.P.B.; Guchelaar, H. & Pereira, A.M. (2011), Failing hormones.
- Deenen, M.J.; Tol, J.; Burylo, A.M.; Doodeman, V.D.; Boer, A. de; Vincent, A.; Guchelaar, H.J.; Smits, P.H.M.; Beijnen, J.H.; Punt, C.J.A.; Schellens, J.H.M. & Cats, A. (2011), Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer, Clinical Cancer Research 17(10): 3455-3468.
- Staveren, M.C. van; Theeuwes-Oonk, B.; Guchelaar, H.J.; Kuilenburg, A.B.P. van & Maring, J.G. (2011), Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency, Cancer Chemotherapy and Pharmacology 68(6): 1611-1617.
- Swen, J.J.; Nijenhuis, M.; Boer, A. de; Grandia, L.; Maitland-van der Zee, A.H.; Mulder, H.; Rongen, G.A.P.J.M.; Schaik, R.H.N. van; Schalekamp, T.; Touw, D.J.; Weide, J. van der; Wilffert, B.; Deneer, V.H.M. & Guchelaar, H.J. (2011), Pharmacogenetics: From Bench to Byte-An Update of Guidelines.
- Relling, M.V.; Guchelaar, H.J.; Roden, D.M. & Klein, T.E. (2011), Pharmacogenetics: Call to Action.
- Dervieux T, Wessels J, Kremer JM, Padyukov L, Seddighzadeh M, Saevarsdottir S, van Vollenhoven RF, Klareskog L, Huizinga T & Guchelaar HJ (2011), Patterns of Interaction Between Genetic and Non-Genetic Attributes and Methotrexate Efficacy in Rheumatoid Arthritis, Arthritis and Rheumatism 63(10): S331-S332.
- Lemos, C.; Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G.; Scheffer, G.L.; Straaten, T. van der; D'Incecco, A.; Falcone, A.; Guchelaar, H.J.; Danesi, R.; Santoro, A.; Giaccone, G.; Tibaldi, C. & Peters, G.J. (2011), Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients, Pharmacogenomics 12(2): 159-170.
- Coenen, M.J.H.; Umicevic-Mirkov, M.; Wessels, J.A.; Vermeulen, S.H.; Toonen, E.J.; Lee, A.T.; Makkinje, R.R.; Kievit, W.; Scheffer, H.; Jansen, T.L.; Dutmer, E.A.; Radstake, T.R.D.; Laar, M.A.F. van de; Barrera, P.; Riel, P.L.C. van; Guchelaar, H.J.; Gregersen, P.K. & Franke, B. (2011), Genome-Wide Association Analysis of Rheumatoid Arthritis Patients Treated with Anti-TNF Medication, Arthritis and Rheumatism 63(10): S60-S60.
- Dervieux, T.; Wessels, J.; Kremer, J.M.; Huizinga, T.W.J. & Guchelaar, H.J. (2011), Gene-Gene Interactions in Folate Pathway Contribute to Methotrexate Adverse Events in Rheumatoid Arthritis, Arthritis and Rheumatism 63(10): S331-S331.
- Swen, J.J. & Guchelaar, H.J. (2011), Comment: Global Formulary Review: How Do We Integrate Pharmacogenomic Information?, Annals of Pharmacotherapy 45(7-8): 1030-1030.
- Rommers, M.K.; Teepe-Twiss, I.M. & Guchelaar, H.J. (2011), A Computerized Adverse Drug Event Alerting System Using Clinical Rules A Retrospective and Prospective Comparison with Conventional Medication Surveillance in the Netherlands.
- Swen, J.J.; Straaten, T. van der; Wessels, J.A.M.; Bouvy, M.L.; Vlassak, E.E.W.; Assendelft, W.J.J. & Guchelaar, H.J. (2011), Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19., European Journal of Clinical Pharmacology.
- Erp, N.P. van; Baker, S.D.; Zandvliet, A.S.; Ploeger, B.A.; Hollander, M. den; Chen, Z.Y.; Hartigh, J. den; Konig-Quartel, J.M.C.; Guchelaar, H.J. & Gelderblom, H. (2011), Marginal increase of sunitinib exposure by grapefruit juice, Cancer Chemotherapy and Pharmacology 67(3): 695-703.
- Steeghs, N.; Mathijssen, R.H.J.; Wessels, J.A.M.; Graan, A.J. de; Straaten, T. van der; Mariani, M.; Laffranchi, B.; Comis, S.; Jonge, M.J.A. de; Gelderblom, H. & Guchelaar, H.J. (2011), Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib, Investigational New Drugs 29(5): 953-962.
- Perwitasari, D.A.; Wessels, J.A.M.; Straaten, R.J.H.M. van der; Baak-Pablo, R.F.; Mustofa, M.; Hakimi, M.; Nortier, J.W.R.; Gelderblom, H. & Guchelaar, H.J. (2011), Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy, Japanese Journal of Clinical Oncology 41(10): 1168-1176.
- Perwitasari, D.A.; Gelderblom, H.; Atthobari, J.; Mustofa, M.; Dwiprahasto, I.; Nortier, J.W.R. & Guchelaar, H.J. (2011), Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics, International Journal of Clinical Pharmacy 33(1): 33-43.
- Erp, N.P. van; Guchelaar, H.J.; Ploeger, B.A.; Romijn, J.A.; Hartigh, J. den & Gelderblom, H. (2011), Mitotane has a strong and a durable inducing effect on CYP3A4 activity, European Journal of Endocrinology 164(4): 621-626.
- Veldt, A.A.M. van der; Eechoute, K.; Gelderblom, H.; Gietema, J.; Guchelaar, H.J.; Erp, N.P. van; Eertwegh, A.J.M. van den; Haanen, J.B.; Mathijssen, R.H.J. & Wessels, J.A.M. (2011), Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib., Clinical Cancer Research 17(3): 620-629.
- Baas, J.M.; Krens, L.L.; Guchelaar, H.J.; Morreau, H. & Gelderblom, H. (2011), Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review.
- Swen, J.J.; Guchelaar, H.J.; Baak-Pablo, R.F.; Assendelft, W.J.J. & Wessels, J.A.M. (2011), Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment, Pharmacogenetics and Genomics 21(8): 461-468.
- Houtsma, D.; Guchelaar, H.J. & Gelderblom, H. (2010), Pharmacogenetics in Oncology: A Promising Field, Current Pharmaceutical Design 16(2): 155-163.
- Guchelaar, H.J. (2010), Pharmacogenetics: Current Status and Future Perspectives, Current Pharmaceutical Design 16(2): 135-135.
- Arbouw, M. el; Guchelaar, H.J. & Egberts, T.C.G. (2010), Novel insights in pharmacogenetics of drug response in Parkinson's disease, Pharmacogenomics 11(2): 127-129.
- Press, R.R.; Fijter, J.W. de & Guchelaar, H.J. (2010), Individualizing Calcineurin Inhibitor Therapy in Renal Transplantation - Current Limitations and Perspectives, Current Pharmaceutical Design 16(2): 176-186.
- Kooloos, W.M.; Wessels, J.A.M.; Straaten, T. van der; Allaart, C.F.; Huizinga, T.W.J. & Guchelaar, H.J. (2010), Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis, Pharmacogenomics 11(2): 163-175.
- Dezentje, V.O.; Blijderveen, N.J.C. van; Gelderblom, H.; Putter, H.; Herk-Sukel, M.P.P. van; Casparie, M.K.; Egberts, A.C.G.; Nortier, J.W.R. & Guchelaar, H.J. (2010), Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer, Journal of Clinical Oncology 28(14): 2423-2429.
- Zandvliet, M.L.; Liempt, E. van; Jedema, I.; Veltrop-Duits, L.A.; Willemze, R.; Guchelaar, H.J.; Falkenburg, J.H.F. & Meij, P. (2010), Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy, Cytotherapy 12(7): 933-944.
- Koomen, E.R.; Vries, E. de; Kempen, L.C. van; Akkooi, A.C.J. van; Guchelaar, H.J.; Louwman, M.W.J.; Nijsten, T. & Coebergh, J.W.W. (2010), Epidemiology of Extracutaneous Melanoma in the Netherlands, Cancer Epidemiology, Biomarkers and Prevention 19(6): 1453-1459.
- Degreef, L.E.; Opdam, F.L.; Teepe-Twiss, I.M.; Jukema, J.W.; Guchelaar, H.J. & Tamsma, J.T. (2010), The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients, European Journal of Internal Medicine 21(4): 293-296.
- Moes, D.J.A.R.; Press, R.R.; Fijter, J.W. de; Guchelaar, H.J. & Hartigh, J. den (2010), Liquid Chromatography-Tandem Mass Spectrometry Outperforms Fluorescence Polarization Immunoassay in Monitoring Everolimus Therapy in Renal Transplantation, Therapeutic Drug Monitoring 32(4): 413-419.
- Arbouw, M.E.L.; Movig, K.L.L.; Koopmann, M.; Poels, P.J.E.; Guchelaar, H.J.; Egberts, T.C.G.; Neef, C. & Vugt, J.P.P. van (2010), Glycopyrrolate for sialorrhea in Parkinson disease A randomized, double-blind, crossover trial, Neurology 74(15): 1203-1207.
- Baak-Pablo, R.; Dezentje, V.; Guchelaar, H.J. & Straaten, T. van der (2010), Genotyping of DNA Samples Isolated from Formalin-Fixed Paraffin-Embedded Tissues Using Preamplification, Journal of Molecular Diagnostics 12(6): 746-749.
- Kooloos, W.M.; Huizinga, T.W.J.; Guchelaar, H.J. & Wessels, J.A.M. (2010), Pharmacogenetics in Treatment of Rheumatoid Arthritis, Current Pharmaceutical Design 16(2): 164-175.
- Press, R.R.; Ploeger, B.A.; Hartigh, J. den; Straaten, T. van der; Pelt, H. van; Danhof, M.; Fijter, H. de & Guchelaar, H.J. (2010), Explaining variability in ciclosporin exposure in adult kidney transplant recipients, European Journal of Clinical Pharmacology 66(6): 579-590.
- Swen, J.J.; Wessels, J.A.M.; Krabben, A.; Assendelft, W.J.J. & Guchelaar, H.J. (2010), Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus, Pharmacogenomics 11(11): 1517-1523.
- Haas, E.C. de; Zwart, N.; Meijer, C.; Suurmeijer, A.J.H.; Meijer, K.; Guchelaar, H.J.; Hoekstra, H.J.; Leeuwen, F.E. van; Sleijfer, D.T.; Boezen, H.M. & Gietema, J.A. (2010), Association of PAI-1 Gene Polymorphism With Survival and Chemotherapy-Related Vascular Toxicity in Testicular Cancer, Cancer 116(24): 5628-5636.
- Rommers, M.K.; Zegers, M.H.; Clercq, P.A. de; Bouvy, M.L.; Meijer, P.H.E.M. de; Teepe-Twiss, I.M. & Guchelaar, H.J. (2010), Development of a computerised alert system, ADEAS, to identify patients at risk for an adverse drug event, Quality and Safety in Health Care 19(6): -.
- Pander, J.; Wessels, J.A.M.; Gelderblom, H.; Straaten, T. van der; Punt, C.J.A. & Guchelaar, H.J. (2010), Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
- Dezentje, V.O.; Blijderveen, N.J.C. van; Gelderblom, H.; Putter, H.; Herk-Sukel, M.P.P. van; Casparie, M.K.; Egberts, A.C.G.; Nortier, J.W.R. & Guchelaar, H.J. (2010), Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen Reply, Journal of Clinical Oncology 28(29): E586E586.
- Pander, J.; Gelderblom, H.; Antonini, N.F.; Tol, J.; Krieken, J.H.J.M. van; Straaten, T. van der; Punt, C.J.A. & Guchelaar, H.J. (2010), Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer, European Journal of Cancer 46(10): 1829-1834.
- Erp, N.P. van; Mathijssen, R.H.J.; Veldt, A.A. van der; Haanen, J.B.; Reyners, A.K.L.; Eechoute, K.; , E. boven; Wessels, J.A.M.; Guchelaar, H.J. & Gelderblom, H. (2010), Myelosuppression by sunitinib is flt-3 genotype dependent, British Journal of Cancer 103(5): 757-758.
- Pander, J.; Wessels, J.A.M.; Mathijssen, R.H.J.; Gelderblom, H. & Guchelaar, H.J. (2010), Pharmacogenetics of tomorrow: the 1+1=3 principle, Pharmacogenomics 11(7): 1011-1017.
- Pander, J.; Gelderblom, H.; Straaten, T. van der; Punt, C.J.A. & Guchelaar, H.J. (2010), Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array', British Journal of Cancer 102(12): 1791-1792.
- Krens, L.L.; Baas, J.M.; Gelderblom, H. & Guchelaar, H.J. (2010), Therapeutic modulation of k-ras signaling in colorectal cancer, Drug Discovery Today 15(13-14): 502-516.
- Zandvliet, M.L.; Falkenburg, J.H.F.; Liempt, E. van; Veltrop-Duits, L.A.; Lankester, A.C.; Kalpoe, J.S.; Kester, M.G.D.; Steen, D.M. van der; Tol, M.J. van; Willemze, R.; Guchelaar, H.J.; Schilham, M.W. & Meij, P. (2010), Combined CD8(+) and CD4(+) adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection, Haematologica 95(11): 1943-1951.
- Perwitasari, D.A.; Atthobari, J.; Dwiprahasto, I.; Hakimi, M.; Gelderblom, H.; Nortier, J.W.R.; Guchelaar, H.J. & Kaptein, A.A. (2010), TRANSLATION AND VALIDATION OF EORTC QLQ-C30 INTO INDONESIAN VERSION FOR CANCER PATIENTS IN INDONESIA, Value in Health 13(7): A515A515.
- Pander, J.; Guchelaar, H.J. & Gelderblom, H. (2010), Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet, Current Opinion in Molecular Therapeutics 12(6): 654-661.
- Engelse MA, Loomans CJ, Oostendorp J, Ringers J, van Rossenberg EH, Steeneveld E, Overdevest JJ, Guchelaar HJ, van Bockel JH, Romijn HA, Fibbe WE, Zwaginga JJ, Rabelink TJ & de Koning EJ (2009), Initiation of a islet isolation program in The Netherlands, Xenotransplantation 16(5): 398-398.
- Kweekel DM, Antonini NF, Nortier JWR, Punt CJA, Gelderblom H & Guchelaar HJ (2009), Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array, British Journal of Cancer 101(2): 357-362.
- Tanja LH, Guchelaar HJ & Gelderblom H (2009), Pharmacogenetics in chemotherapy of colorectal cancer.
- Dezentje V, Van Blijderveen NJ, Gelderblom H, Putter H, Van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW & Guchelaar HJ (2009), Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study, Journal of Clinical Oncology 27(18).
- Albers HM, Wessels JAM, van der Straaten RJHM, Brinkman DMC, Suiilekom-Smit LWA, Kamphuis SSM, Girschick HJ, Wouters C, Schilham MW & le Cessie S (2009), Time to Treatment as an Important Factor for the Response to Methotrexate in Juvenile Idiopathic Arthritis, Arthritis and Rheumatism 61(1): 46-51.
- Schellens JHM, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, de Boer A & Van Bortel LM (2009), The Dutch Vision of Clinical Pharmacology, Clinical Pharmacology and Therapeutics 85(4): 366-368.
- van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AKL, Mathijssen RHJ, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JAM, Guchelaar HJ & Gelderblom H (2009), Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity, Journal of Clinical Oncology 27(26): 4406-4412.
- Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt H, Danhof M, de Fijter H & Guchelaar H (2009), OPTIMIZING CALCINEURIN INHIBITOR EXPOSURE IN KIDNEY TRANSPLANT RECIPIENTS EARLY AFTER TRANSPLANTATION, Clinical Pharmacology and Therapeutics 85: S38S38.
- Wassenaar MJE, Biermasz NR, Pereira AM, van der Klaauw AA, Smit JWA, Roelfsema F, van der Straaten T, Cazemier M, Hommes DW, Kroon HM, Kloppenburg M, Guchelaar HJ & Romijn JA (2009), The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly, Journal of Clinical Endocrinology and Metabolism 94(12): 4671-4678.
- Joosse A, Koomen ER, Casparie MK, Herings RMC, Guchelaar HJ & Nijsten T (2009), Non-Steroidal Anti-Inflammatory Drugs and Melanoma Risk: Large Dutch Population-Based Case-Control Study, Journal of Investigative Dermatology 129(11): 2620-2627.
- Koomen ER, Herings RMC, Guchelaar HJ & Nijsten T (2009), Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, Cancer Epidemiology 33(5): 391-395.
- Press RR, van Rossum HH, Ploeger BA, den Hartigh J, van Pelt J, Guchelaar HJ, de Fijter JW & Danhof M (2009), Is Calcineurin Activity Useful as a Biomarker to Optimize Cyclosporine a Therapy in Renal Transplant Recipients?, Therapeutic Drug Monitoring 31(5): 620-620.
- Guchelaar HJ (2009), Individualisation of cancer treatment by pharmacogenetics, EJC Supplements 7(2): 33-34.
- Arbouw MEL, Movig KLL, Koopmann M, Poels PJE, Guchelaar HJ, Egberts TCG, Neef C & van Vugt JPP (2009), Glycopyrroniumbromide for the treatment of sialorrhea in parkinson's disease, British Journal of Clinical Pharmacology 68(5): 782-782.
- Kweekel DM, Gelderblom H, Antonini NF, Van der Straaten T, Nortier JWR, Punt CJA & Guchelaar HJ (2009), Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients, European Journal of Cancer 45(4): 572-578.
- van Rijn-Bikker PC, Mairuhu G, van Montfrans GA, Sijbrands EJG, Zwinderman AH, Guchelaar HJ & Koopmans RP (2009), Genetic Factors Are Relevant and Independent Determinants of Antihypertensive Drug Effects in a Multiracial Population, American Journal of Hypertension 22(12): 1295-1302.
- Dervieux T, Wessels JAM, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ & Kremer JM (2009), Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis, Pharmacogenetics and Genomics 19(12): 935-944.
- Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW & Guchelaar HJ (2009), Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients, Therapeutic Drug Monitoring 31(2): 187-197.
- Koomen ER, Joosse A, Herings RMC, Casparie MK, Guchelaar HJ & Nijsten T (2009), Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study, Annals of Oncology 20(2): 358-364.
- Deenen MJ, Burylo A, Tol J, de Boer A, Vincent A, Guchelaar HJ, Punt CJA, Beijnen JH, Cats A & Schellens JHM (2009), DPYD Single nucleotide polymorphisms (SNPS) in metastatic colorectal cancer (MCRC) patients (PTS) treated with capecitabine, oxaliplatin and targeted agents, British Journal of Clinical Pharmacology 68(5): 783-783.
- Zandvliet ML, Falkenburg JHF, Jedema I, Willemze R, Guchelaar HJ & Meij P (2009), Detailed Analysis of IFNg Response Upon Activation Permits Efficient Isolation of Cytomegalovirus-specific CD8(+) T Cells for Adoptive Immunotherapy, Journal of Immunotherapy 32(5): 513-523.
- van Erp NP, Gelderblom H & Guchelaar HJ (2009), Clinical pharmacokinetics of tyrosine kinase inhibitors, Cancer Treatment Reviews 35(8): 692-706.
- Dezentje VO, Guchelaar HJ, Nortier JWR, van de Velde CJH & Gelderblom H (2009), Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer, Clinical Cancer Research 15(1): 15-21.
- Arbouw MEL, Movig KLL, Egberts TCG, Poels PJE, van Vugt JPP, Wessels JAM, van der Straaten RJHM, Neef C & Guchelaar HJ (2009), Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease, European Journal of Clinical Pharmacology 65(12): 1245-1251.
- Koomen ER, Joosse A, Herings RMC, Casparie MK, Guchelaar HJ & Nijsten T (2009), Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy, Melanoma Research 19(5): 327-332.
- Wierenga PC, Lie-A-Huen L, de Rooij SE, Klazinga NS, Guchelaar HJ & Smorenburg SM (2009), Application of the Bow-Tie Model in Medication Safety Risk Analysis Consecutive Experience in Two Hospitals in the Netherlands, Drug Safety 32(8): 663-673.
- van Erp N, Mathijssen RH, van der Veldt AA, Haanen JB, Reyners AK, Eechoute K, Boven E, Wessels JA, Guchelaar H & Gelderblom H (2009), Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity, Journal of Clinical Oncology 27(15).
- Kooloos WM, Guchelaar HJ, Huizinga TWJ & Wessels JAM (2009), Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate, Rheumatology 48(9): 1176-1177.
- Kooloos WM, Wessels JAM, van der Straaten T, Huizinga TWJ & Guchelaar HJ (2009), Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study, Drug Discovery Today 14(17-18): 837-844.
- Kooloos WM, Wessels JAM, van der Kooij SM, Allaart CF, Huizinga TWJ & Guchelaar HJ (2009), Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond, Annals of the Rheumatic Diseases 68(8): 1371-1371.
- Kooloos WM, Wessels JAM, van der Kooij SM, Allaart CF, Huizinga TWJ & Guchelaar HJ (2009), Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond, Annals of the Rheumatic Diseases 68(8): 1371-1371.
- van der Klaauw AA, van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JWA & Romijn JA (2008), Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults, Journal of Clinical Endocrinology and Metabolism 93(7).
- Zwaveling J, Press RR, Bredius RGM, van der Straaten TRJHM, den Hartigh J, Bartelink IH, Boelens JJ & Guchelaar HJ (2008), Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients, Therapeutic Drug Monitoring 30(4).
- Joosse A, Koomen ER, Guchelaar HJ & Nijsten T (2008), The effect of NSAIDs on the incidence of cutaneous melanoma, Journal of Investigative Dermatology 128(10).
- Kweekel D, Guchelaar HJ & Gelderblom H (2008), Clinical and pharmacogenetic factors associated with irinotecan toxicity, Cancer Treatment Reviews 34(7).
- Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJA & Guchelaar HJ (2008), UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study, British Journal of Cancer 99(2).
- Dezentje VO, Nortier JWR, Guchelaar HJ, van de Velde CJH & Gelderblom H (2008), Clinical implications of CYP2D6 genotyping on tamoxifen treatment in breast cancer, EJC Supplements 6(7).
- Schellens JHM, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, de Boer A & Van Bortel LM (2008), The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist-clinical pharmacologists, British Journal of Clinical Pharmacology 66(1).
- Arbouw MEL, Movig KLL, Guchelaar HJ, Poels PJE, van Vugt JPP, Neef C & Egberts TCG (2008), Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trials, European Journal of Clinical Pharmacology 64(10).
- Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JWR, Gelderblom H, Punt CJA & Guchelaar HJ (2008), GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group, British Journal of Cancer 99(8).
- van Kan HJM, van den Berg LH, Groeneveld GJ, van der Straaten RJHM, van Vught PWJ, Lie-A-Huen L & Guchelaar HJ (2008), Pharmacokinetics of riluzole: Evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype, Biopharmaceutics and Drug Disposition 29(3).
- van der Straaten T, Swen J, Baak-Pablo R & Guchelaar HJ (2008), Use of plasmid-derived external quality control samples in pharmacogenetic testing, Pharmacogenomics 9(9).
- Guchelaar HJ (2008), Hospital pharmacy as a research area in its own right, EJHP Practice 14(1).
- van Kuilenburg ABP, Klumpen HJ, Westermann AM, Zoetekouw L, Bakker PJM, Guchelaar HJ & Richel DJ (2008), Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy, Nucleosides, Nucleotides and Nucleic Acids 27(6-7).
- Van Der Kooij SM, Wessels JAM, Huizinga TWJ & Guchelaar HJ (2008), Comment on: The pharmacogenetics of methotrexate, Rheumatology 47(4).
- Wessels JAM, van der Kooij SM, Huizinga TWJ & Guchelaar HJ (2008), Identity of single-nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: comment on the article by Wessels et al - Reply, Arthritis and Rheumatism 58(4).
- Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, de Boer A, Conemans JMH, Egberts TCG, Klungel OH, Koopmans R, van der Weide J, Wilffert B, Guchelaar HJ & Deneer VHM (2008), Pharmacogenetics: From bench to byte, Clinical Pharmacology and Therapeutics 83(5).
- Groeneveld GJ, van Kan H, Lie-A-Huen L, Guchelaar HJ & van den Berg LH (2008), An association study of riluzole serum concentration and survival and disease progression in patients with ALS, Clinical Pharmacology and Therapeutics 83(5).
- Nijsten T, Koomen ER, Joosse A, Herings R, Casparie M & Guchelaar H (2008), Oestrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population based case control study, Journal of Investigative Dermatology 128.
- ten Tusscher GW, Guchelaar HJ, Koch J, Ilsen A, Vulsma T, Westra M, van der Slikke JW, Olie K & Koppe JG (2008), Perinatal dioxin exposure, cytochrome P-450 activity, liver functions and thyroid hormones at follow-up after 7-12 years, Chemosphere 70(10).
- Wessels JAM, Huizinga TWJ & Guchelaar HJ (2008), Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis, Rheumatology 47(3).
- Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier H, Gelderblom H, Punt C & Guchelaar H (2008), GSTPI ILE105VAL POLYMORPHISM AND IRINOTECAN EFFICACY IN METASTATIC COLORECTAL CANCER (MCRC), A STUDY OF THE DUTCH COLORECTAL CANCER GROUP (DCCG), Annals of Oncology 19: 166-166.
- Zandvliet ML, Falkenburg JHF, Veltrop-Duits LA, Schilham MW, Willemze R, Guchelaar HJ & Meij P (2008), Generation of Combined CD8+and CD4+T Cell Lines with High Specificity for Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation, Blood 112(11): 775-776.
- Zandvliet ML, Falkenburg JHF, Jedema I, Willemze R, Guchelaar HJ & Meij P (2008), Universal CD137 Expression upon Activation Allows Efficient Isolation of a Broad Repertoire of Virus-Specific CD8+and CD4+T Cells for Adoptive Immunotherapy, Blood 112(11): 774-775.
- Zandvliet ML, Falkenburg JHF, Kester MGD, de Ru AH, van Veelen PA, Willemze R, Guchelaar HJ & Meij P (2008), Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation, Blood 112(11): 1330-1331.
- van Erp N, Gelderblom H, Van Glabbeke M, Van Oosterorn A, Verweij J, Guchelaar HJ, Debiec-Rychter M, Peng B, Blay JY & Judson I (2008), Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC, Clinical Cancer Research 14(24): 8308-8313.
- Schimmel K, van Lenthe H, Leen R, Kulik W, Verschuur A, Guchelaar HJ & van Kuilenburg A (2008), Quantitative analysis of the experimental cytotoxic drug cyclopentenyl cytosine and its metabolite in plasma with HPLC tandem mass spectrometry.
- Erp Nielka P.H. van, Oostendorp Roos L., Guchelaar Henk-Jan, Schellens Jan H.M. & Gelderblom Hans (2007), Is rectal administration an alternative route for imatinib?, Cancer Chemotherapy and Pharmacology 60(4): 623-624.
- Wessels Judith A. M., van der Kooij Sjoerd M., le Cessie Saskia, Kievit Wietske, Barerra Pilar, Allaart Cornelia F., Huizinga Tom W. J. & Guchelaar Henk-Jan (2007), A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis, Arthritis and Rheumatism 56(6): 1765-1775.
- Wessels JAM, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, Huizinga TWJ & Guchelaar HJ (2007), A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis, Arthritis and Rheumatism 56(6).
- van Erp NR, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD & Sparreboom A (2007), Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib, Clinical Cancer Research 13(24).
- Pander J, Gelderblom H & Guchelaar HJ (2007), Pharmacogenetics of EGFR and VEGP inhibition, Drug Discovery Today 12(23-24).
- Koomen ER, Joosse A, Herings RMC, Casparie MK, Bergman W, Nijstene T & Guchelaar HJ (2007), Is station use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?, European Journal of Cancer 43(17).
- Schimmel KJM, Nijmeijer BA, van Schie MLJ, Falkenburg JHF & Guchelaar HJ (2007), Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia, Leukemia Research 31(11).
- Rommers MK, Teepe-Twiss IM & Guchelaar HJ (2007), Preventing adverse drug events in hospital practice: an overview, Pharmacoepidemiology and Drug Safety 16(10).
- Schimmel KJM, Gelderblom H & Guchelaar HJ (2007), Cyclopentenyl Cytosine (CPEC): An overview of its in vitro and in vivo activity, Current Cancer Drug Targets 7(5).
- Swen JJ, Huizinga TW, Gelderblom H, de Vries EGE, Assendelft WJJ, Kirchheiner J & Guchelaar HJ (2007), Translating pharmacogenomics: Challenges on the road to the clinic, PLoS Medicine 4(8).
- Press RR, Ploeger BA, den Hartigh J, van der Straaten RJHM, van Pelt J, Danhof M, de Fijter JW & Guchelaar HJ (2007), Dose prediction of tacrolimus in de novo kidney transplant patients with population pharmacokinetic modelling including genetic polymorphisms, Therapeutic Drug Monitoring 29(4).
- Press RR, Ploeger BA, den Hartigh J, Bemelman FJ, van der Heides JJH, Danhof M, Guchelaar HJ & de Fijter JW (2007), TDM of everolimus in stable renal transplant patients after CNI withdrawal, Therapeutic Drug Monitoring 29(4).
- van Erp NPH, Oostendorp RL, Guchelaar HJ, Schellens JHM & Gelderblom H (2007), Is rectal administration an alternative route for imatinib?
- Pander J, Gelderblom H & Guchelaar HJ (2007), Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs, Expert Opinion on Pharmacotherapy 8(9).
- Press RR, Ploeger BA, den Hartigh J, van der Straaten RJHM, van Pelt J, Danhof M, de Fijter JW & Guchelaar HJ (2007), Improved dose prediction of tacrolimusin de novo kidney transplant patients with population pharmacokinetic modelling including genetic polymorphismis., American Journal of Transplantation 7.
- Arbouw MEL, Movig KLL, Guchellar HJ, Poels PJE, van Vugt JPP, Neef C & Egberts TCG (2007), Persistence of new dopaminergic agents in clinical practice remarkably comparable with clinical trial data, Pharmacoepidemiology and Drug Safety 16.
- Meij P, Zandvliet ML, van der Heiden PLJ, Jedema I, Egmond EM, Cox LMP, de Meent MV, Bongaerts R, Hoogstraten C, Guchelaar HJ, Willemze R & Falkenburg JHF (2007), Generation and administration of CMV pp65-specific donor T-cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation, Bone Marrow Transplantation 39.
- Kooloos WM, de Jong DJ, Huizinga TWJ & Guchelaar HJ (2007), Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease, Drug Discovery Today 12(3-4).
- Arbouw MEL, van Vugt JPP, Egberts TCG & Guchelaar HJ (2007), Pharmacogenetics of antiparkinsonian drug treatment: a systematic review, Pharmacogenomics 8(2).
- van der Straaten RJHM, Wessels JAM, de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Allaart CF, Tiller M, Huizinga TWJ & Guchelaar HJ (2007), Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in metho trexate-treated rheumatoid arthritis patients, Pharmacogenomics 8(2).
- van Kuilenburg ABP, Klumpen HJ, Westermann AM, Zoetekouw L, Van Lenthe H, Bakker PJM, Richel DJ & Guchelaar HJ (2007), Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin, European Journal of Cancer 43(2).
- Wessels JAM, Huizinga TWJ, Guchelaar HJ & de Jonge R (2007), Effect of the 34C > T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al - Reply, Arthritis and Rheumatism 56(2).
- Arbouw MEL, Movig KLL, Neef C, Guchelaar HJ & Egberts TCG (2007), Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients, European Journal of Clinical Pharmacology 63(2).
- Wessels JAM, Kooloos WM, de Jonge R, de Vries-Bouwstra JK, Allaart CF, Linssen A, Collee G, de Sonnaville P, Lindemans J, Huizinga TWJ & Guchelaar HJ (2006), Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis, Arthritis and Rheumatism 54(9).
- Wessels JAM, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YPM, Allaart CF, Kerstens PJSM, van Zeben D, Breedveld FC, Dijkmans BAC, Huizinga TWJ & Guchelaar HJ (2006), Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes, Arthritis and Rheumatism 54(4).
- Schimmel K, Guchelaar HJ & van Kan E (2006), Formulation, quality control and shelf life of the experimental cytostatic drug cyclopentenyl cytosine, Drug Development and Industrial Pharmacy 32(4).
- Zwaveling J, den Hartigh J, Lankester AC, Guchelaar HJ, Egeler RM & Bredius RGM (2006), Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomeos, Anti-Cancer Drugs 17(9).
- van der Straaten T, Kweekel D, Tiller M, Bogaartz J & Guchelaar HJ (2006), Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1, Journal of Molecular Diagnostics 8(4).
- Wessels JAM, Huizinga TWJ & Guchelaar HJ (2006), Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: comment on the article by Wessels et al - Reply, Arthritis and Rheumatism 54(10).
- Wessels JAM, de Vries-Bouwstra JK, Heijmans BT, Goekoop-Ruiterman YPM, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BAC, Huizinga TWJ & Guchelaar HJ (2005), Single nucleotide polymorphisms in genes coding for folate pathway enzymes are determinants for methotrexate efficacy in early rheumatoid arthritis, Arthritis and Rheumatism 52(9).
- van Erp NPH, Baker SD, Zhao M, Rudek M, Guchelaar HJ, Nortier JWR, Sparreboom A & Gelderblom H (2005), Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan, Clinical Cancer Research 11(21).
- Schimmel KJM, Nijmeijer BA, van Schie MLJ, Falkenburg JHF & Guchelaar HJ (2005), Toxicity and effectivity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia (ALL)., Blood 106(11).
- Wessels JAM, De Vries-Bouwstra JK, Heijmans BT, Goekoop-Ruiterman YPM, Allaart CF, Kerstens PJS, Van Zeben D, Breedveld FC, Dijkmans BAC, Huizinga TWJ & Guchelaar H (2005), Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single nucleotide polymorphisms in genes coding for folate pathway enzymes, Annals of the Rheumatic Diseases 64.
- Kweekel DM, Gelderblom H & Guchelaar HJ (2005), Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy, Cancer Treatment Reviews 31(2).
- Schimmel K, Bennink R, de Bruin K, Leen R, Sand K, van den Hoff M, van Kuilenburg A, Vanderheyden JL, Steinmetz N, Pfaffendorf M, Verschuur A & Guchelaar HJ (2005), Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats, Archives of Toxicology 79(5).
- van Kan HJM, Groeneveld GJ, Kalmijn S, Spieksma M, van den Berg LH & Guchelaar HJ (2005), Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis, British Journal of Clinical Pharmacology 59(3).
- Guchelaar HJ, Colen HBB, Kalmeijer MD, Hudson PTW & Teepe-Twiss IM (2005), Medication errors - Hospital pharmacist perspective, Drugs 65(13).
- Ramrattan MA, Elfrink F, Guchelaar HJ & Mulder WMC (2004), Adverse drug events at hospital admission: comparison of case-identification methods, British Journal of Clinical Pharmacology 58(1).
- Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ & Guchelaar HJ (2004), The risk of cancer in users of statins, Journal of Clinical Oncology 22(12).
- van Kan HJM, Spieksma M, Groeneveld GJ, Torano JS, van den Berg LH & Guchelaar HJ (2004), A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis, Biomedical Chromatography 18(9).
- Graaf MR, Richel DJ, van Noorden CJF & Guchelaar HJ (2004), Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer, Cancer Treatment Reviews 30(7).
- Guchelaar HJ, Kalmeijer MD & Jansen MEP (2004), Medication error due to ambiguous labelling of a commercial product, Pharmacy World and Science 26(1).
- Merkus P, Guchelaar HJ, Bosch DA & Merkus FWHM (2004), Nasal drug delivery to the cerebrospinal fluid: transport of a hydrophilic drug, British Journal of Clinical Pharmacology 57(3).
- van Kan HJM, Groeneveld GJ, Torano JS, Spieksma M, van den Berg LH & Guchelaar HJ (2004), Correlation between riluzole clearance and CYP1A2 activity in patients with amyotrophic lateral sclerosis, British Journal of Clinical Pharmacology 57(3).
- Rigter IM, Schipper HG, Koopmans RP, van Kan HJM, Frijlink HW, Kager PA & Guchelaar HJ (2004), Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers, Antimicrobial Agents and Chemotherapy 48(3).
- Schimmel KJM, Richel DJ, van den Brink RBA & Guchelaar HJ (2004), Cardiotoxicity of cytotoxic drugs, Cancer Treatment Reviews 30(2).
- Fuchs SA, Meyboom RHB, van Puijenbroek EP & Guchelaar HJ (2004), Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema, Pharmacy World and Science 26(4).
- Cremers S, Van Zuylen L, Gelderblom H, Seynaeve C, Guchelaar HJ, Pols H, Vermeij P, Van der Rijt C & Papapoulos S (2004), Whole body retention in relation to rate of bone resorption after intravenous bisphosphonate (pamidronate) in patients with breast cancer and bone metastases., Journal of Clinical Oncology 22(14).
- Schimmel KJM, Bennink RJ, de Bruin KM, Sand K, van Kuilenburg ABP, Vanderheyden JL, Steinmetz N, van den Hoff MJ, Pfaffendorf M, Verschuur AC & Guchelaar HJG (2004), Use of Tc-99m-Annexin V to study cardiotoxicity of the cytotoxic drug cyclopentenyl cytosine (CPEC) in rats, European Journal of Nuclear Medicine and Molecular Imaging 31.
- Kweekel DM, Le Cessie S, Guchelaar HJ, Vermeij P, Van Den Broek PJ & Twiss IM (2004), Outcomes of an antimicrobial control program in a Dutch hospital, American Journal of Health-System Pharmacy 61(16).
- Vermes A, Kuijper EJ, Guchelaar HJ & Dankert J (2003), An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora, Chemotherapy 49(1-2).
- Merkus P, Guchelaar HJ, Bosch A & Merkus FWHM (2003), Direct access of drugs to the human brain after intranasal drug administration?, Neurology 60(10).
- Guchelaar HJ (2003), Risk and the sense of safety, Pharmacy World and Science 25(3).
- Guchelaar HJ & Kalmeijer MD (2003), The potential role of computerisation and information technology in improving prescribing in hospitals, Pharmacy World and Science 25(3).
- Kalmeijer MD, Holtzer W, van Dongen R & Guchelaar HJ (2003), Implementation of a computerized physician medication order entry system at the Academic Medical Centre in Amsterdam, Pharmacy World and Science 25(3).
- Hudson PTW & Guchelaar HJ (2003), Risk assessment in clinical pharmacy, Pharmacy World and Science 25(3).
- van Troostwijk LJAED, Koopmans RP & Guchelaar HJ (2003), Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio, Fundamental and Clinical Pharmacology 17(3).
- van Olden RW, Guchelaar HJ, Struijk DG, Krediet RT & Arisz L (2003), Acute effects of high-dose furosemide on residual renal function in CAPD patients, Peritoneal Dialysis International 23(4).
- Groeneveld GJ, Van Kan HJM, Kalmijn S, Veldink JH, Guchelaar HJ, Wokke JHJ & Van den Berg LH (2003), Riluzole serum concentrations in patients with ALS - Associations with side effects and symptoms, Neurology 61(8).
- van Troostwijk LJAED, Koopmans RP, Vermeulen HDB & Guchelaar HJ (2003), CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients, European Journal of Pharmaceutical Sciences 20(4-5).
- Lid
- Voorzitter
- Lid van de Raad voor de Medische Wetenschappen
- lid